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CHAPTER 1: INTRODUCTION
The maintenance of homeostasis is integral to ocular function and for this, a
specific corneal anatomy must be preserved for accurate interpretation and
processing of light by the retina. In general, corneal healing seeks to preserve
eye integrity, restore the epithelium’s barrier function, safeguard corneal clarity to
provide vision, and thwart microbial invasion until other immunological
mechanisms can respond. Regardless of the type of injury, the response is rapid
and the cornea is “primed and ready” to respond immediately to damage (Wilson
et al., 2001).
Corneal Anatomy
The human (and murine) cornea is composed of an outer epithelium,
underlying stroma, and an endothelium. Bowman’s layer underlies the epithelium
(human), below which is the stroma, while the endothelium sits upon a basement
membrane, referred to as Descemet’s Membrane. In normal corneal anatomy, a
sub-basal plexus of penetrating nerve fibers overlie Bowman’s layer (basement
membrane in the mouse) and sends perpendicular beaded neuronal projections
through the epithelium, toward the corneal surface (Fig. 1A, B). These branches
are sensory, sympathetic, or parasympathetic and have a variety of functions,
including sensory perception and the delivery of neuropeptides to the tissue
(Marfurt et al., 2009; Muller et al., 2003; Muller et al., 1996). Corneal innervation
has increasingly become an area of interest because of the clinical importance of
pathologies in which nerves are damaged (e.g., microbial infection, neurotrophic
keratitis, and diabetes).
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Figure 1. (A) Neuronal penetration of the corneal epithelium (a. sub-basal nerve; b. fibers
entering the epithelium; c. intra-epithelial network) (Yeo, 1889). (B) Composite confocal image of
human corneal innervation (Patel and McGhee, 2009).

The Immune Response
The cornea is equipped with mechanisms to control endogenous colonizing
microflora homeostasis and pathological invaders. These defenses are
comprised of anatomical (e.g., epithelium), mechanical (e.g., tight junctions), and
chemical (e.g., antimicrobial agents, enzymes) barriers, as well as inducible
immune defense networks: the innate and adaptive immune systems. During
infection, the latter work sequentially and in concert to expunge the cornea of
microbial agents (Albiger et al., 2007).
Innate immunity is rapid, immediate, and non-specific with cells that instruct
the more specific adaptive system. Thereafter, the adaptive system retains a
“memory” for a given pathogen so it may mount increasingly effective responses
to repeat encounters. In part, this is based on “the rearrangement and clonal
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expansion of a random repertoire of antigen receptors”, including the Toll-like
receptors (TLR) present on lymphocytes and other cells (Albiger et al., 2007).
There are three principal components to the immune system’s response to
infection: increased blood supply to the area, increased vascular permeability,
and the migration of leukocytes from vessels into the surrounding tissue (i.e.,
extravasation).

During

an

acute

(early)

immunological

response,

polymorphonuclear neutrophils (PMN) are signaled to exit the blood stream and
infiltrate the extracellular matrix (ECM). This process, referred to as chemotaxis,
is instigated in the human cornea by signaling molecules such as interleukin-8
(IL-8, functional homologue of murine MIP-2) and C5a (a component of the
complement system) (Hazlett, 2004; Kuo et al., 2000).
PMN have several functions during bacterial infection: release of cytokines to
amplify inflammation, phagocytosis of invading pathogens, and degranulation, or,
the release of antimicrobial proteins (e.g., defensins) and other components from
cytoplasmic granules (Segal, 2005). Recently, studies also have determined that
PMN use neutrophil extracellular traps (NETs) in a cell death process (NETosis)
in which chromatin fibers equipped with anti-microbial granules and enzymes are
ejected from the cell to immobilize and kill invading microorganisms (Kaplan and
Radic, 2012).
Macrophages are another essential leukocyte involved in the immune
response of the cornea. In fact, during bacterial keratitis, regulation of PMN
number in the cornea is a function of macrophages (Hazlett, 2004). In addition,
Brissette-Storkus et al. (2002) has shown that the cornea contains a small, fixed
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resident

population

of

leukocytes

(primarily

monocytes/macrophages)

strategically situated to thwart bacterial invasion. In addition, these cells express
low levels of major histocompatibility complex (MHC) class II and therefore, are
considered antigen-presenting cells (APCs) – a first line of corneal defense
(Brissette-Storkus et al., 2002; van Vugt et al., 1993).
A separate set of macrophages that participate in defense of the cornea are
mobile and infiltrate an affected area approximately 48-96 hours after damage.
Initially, these so-called “wound macrophages” are involved in wound
debridement through phagocytosis and inflammation. Later, they play a pivotal
role in regulating corneal healing through the release of growth factors, enzymes,
and cytokines (Brissette-Storkus et al., 2002; Schaffer et al., 1998).
The cellular response to bacterial infection [e.g., Pseudomonas (P.)
aeruginosa] in the cornea is predominantly neutrophilic (PMN), but CD4+ T-cells
have also been implicated, leading to susceptibility and corneal perforation in
mice (Hazlett et al., 2000). Mosmann and Coffman (1989) have shown that these
T-cells can be subdivided into two distinct groups based on their predominant
cytokine production: Th1 cells [produce interferon (IFN)-γ, interleukin (IL)-12,
tumor necrosis factor (TNF)-α] and Th2 cells (produce IL-4, -5, -10). These
responses control resistance and susceptibility to a variety of microorganisms
including P. aeruginosa (Hazlett et al., 2000). In this regard, microarray studies
have shown that BALB/c mice exhibit a Th2-type (resistant, cornea heals)
phenotype to P. aeruginosa infection while C57BL/6 (B6) mice are Th1
responders (susceptible, cornea perforates) (Huang and Hazlett, 2003) (Fig. 2A,
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Figure 2. Murine corneas infected with P. aeruginosa at 7 days post-infection. (A) The Th1responder “susceptible” strain (B6), and, (B) the Th2-responder “resistant” strain (BALB/c).

B; McClellan et al., 2003).
Lastly, the cornea is a site of immune privilege, an evolutionary mechanism
whereby immune effectors provide local protection without disruption of visual
function (Szliter et al., 2007). Macrophages, PMN, as well as a balance of proand anti-inflammatory cytokine production is critical to maintain immune privilege
in the cornea. The adverse effects of infectious agents in the cornea are the
result of immune privilege loss, which occurs when the immune response to an
invading agent becomes overwhelming, resulting in damage to collateral
bystander cells (Niederkorn, 2011).
The Disease – Bacterial Keratitis
Clinically, ocular bacterial infections often present as a rapidly progressing,
suppurative stromal infiltrate with a marked mucopurulent exudate. The following
features frequently accompany the infection: yellow coagulative necrosis,
inflammatory epithelial edema, stromal ulceration, hypopyon, ring infiltrate,
descemetocele, and corneal perforation (Hazlett, 2004). Complications primarily
consist of alterations to corneal structure, but secondary glaucoma and cataracts
also are seen and some cases may require corneal transplant (Wilhelmus, 1995).
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The Pathogen – Pseudomonas aeruginosa
P. aeruginosa is one of the “most common isolates from patients with
microbial keratitis” (Pachigolla et al., 2007). It is classified as an opportunistic,
Gram-negative

bacterium

that

causes

keratitis

in

patients

who

are

immunocompromised and in extended wear contact lens users. Infection is rapid
and triggers an immune response that, if dysregulated, can lead to vision loss
(Lyczak et al., 2000).
Embedded within its complex cell wall is lipopolysaccharide (LPS, endotoxin);
its presence helps protect the bacterium from host defenses (e.g., complement,
enzymes) and antibiotics, making it crucial for the microbe’s viability. Lipid A is
the component of LPS that is most immunostimulatory and is responsible for a
majority of acute inflammatory responses (Albiger et al., 2007). LPS binds with
LPS-binding protein (LBP) that in turn binds anchored CD-14 on the surface of
the host cell. LPS is then transferred to soluble MD-2 to activate Toll-like receptor
4 (TLR4) and its signaling pathway. Ultimately, this pathway leads to
upregulation of NFκB and increased production of pro-inflammatory cytokines (as
outlined below).
IL-10/IL-12p40 Axis
P. aeruginosa infection in resistant Th2-responder BALB/c mice, elicits
production of both pro- and anti-inflammatory cytokines. Among those that are
defined as anti-inflammatory, IL-10 is critical for balancing cytokines such as IFNγ and decreasing stromal damage, while promoting successful pathogen
elimination (McClellan et al., 2008; McClellan et al., 2003). Although pro-
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inflammatory cytokines such as IL-12p40 are essential to amplify the initial innate
immune response to combat infection, without cytokines such as IL-10
counterbalancing its effects, the inflammatory response becomes dysregulated
and a chronic inflammatory state can occur (Cheekalta et al., 2012, Niemand et
al., 2002; Aste-Amezaga et al., 1998).
IL-10 Effectors
IL-10 acts upon many downstream effectors to elicit its anti-inflammatory
effects, including: signal transducer and activator of transcription-3 (STAT-3),
suppressor of cytokine signaling 3 (SOCS3), matrix metalloproteinase-9 (MMP9), and inducible nitric oxide synthase (iNOS). IL-10 binds with its receptor (IL10R1) to transphosphorylate Jak, activating it, and creating binding sites for
STAT-3. IL-10 primarily signals via STAT-3 (Niemand et al., 2002) and, when
activated, is a proven mediator of inflammatory signals: STAT-3 has been shown
to decrease levels of IL-12p40 and TNF-α (Butcher et al., 2005), and, in a LPS
sepsis model using STAT-3-/- mice, TNF-α levels are elevated and lethality
increased (Takeda et al., 1999). STAT-3 is essential for mediating the effects of
IL-10.
SOCS3 has a critical role in inhibiting STAT-3 activation (Qin et al., 2012) and
plays a pivotal role in regulating cytokine expression during inflammation. It has
been characterized as a mediator of LPS-stimulated IL-10 release in response to
infection (Berlato et al., 2002) and is strongly upregulated in response to IL-10
(Niemand et al., 2002). In addition, SOCS3-deficient mice are vulnerable to
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enhanced expression of Th1 inflammatory cytokines promoting infiltration of
inflammatory cells (e.g., PMN, macrophages, T-cells) (Qin et al., 2012).
Members of the MMP family of gelatinases facilitate infiltration of leukocytes
to the site of inflammation through degradation of the ECM. In the cornea, MMP9 is among the most widely studied as it preferentially degrades basementmembrane components such as type IV collagen [found in Descemet’s
membrane and essential in epithelial cell migration and adhesion (Cameron et
al., 1991)]. Disproportionately elevated levels of MMP-9 foster destruction of the
corneal stromal cytoarchitecture and decrease the ability for tissue restoration.
Treatment of BALB/c mice with rMMP-9 elicits a state of worsened disease:
increased clinical score, myeloperoxidase (MPO) levels, Langerhans cell
number, and protein levels of pro-inflammatory cytokines (McClellan et al.,
2006a). Moreover, treatment with rIL-10 decreases MMP-9 while increasing its
inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1) (Lacraz et al., 1995).
Berlato, et al. (2002) treated cells with IL-10 and observed a correlation
between this treatment and decreased iNOS. In previous reports, our laboratory
has shown that iNOS is constitutively expressed in the resistant BALB/c cornea
and is required for bacterial killing (Hazlett et al., 2005). However, overproduction
of iNOS-derived NO (through upregulation of IFN-γ) is associated with
susceptibility to P. aeruginosa infection (McClellan et al., 2006b).
The Neuropeptides – SP, VIP
Made in the soma of neurons, and by epithelial cells, fibroblasts, and
leukocytes, neuropeptides are small proteins that belong to a vast family of
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extracellular messengers. They can have profound affects on the activities of the
central, autonomic, and peripheral portions of the nervous system and the
tissues they supply. Neuropeptides regulate immune cells (e.g., macrophages),
affect the proliferation of epithelial and endothelial cells and connective tissue
(Schaffer et al., 1998), are involved in neuronal proliferation, and possess
antimicrobial properties (El Karim et al., 2008). They are key regulators of the
neurogenic inflammatory response through promotion of vasodilation, increased
vascular permeability, and recruitment of immunocompetent cells.
In recent years, the link between neuropeptides and the immune system has
been well established (Kin and Sanders, 2006). Evidence for this link is the
presence of neuropeptide receptors on, and the proximity of neuron terminals to
leukocytic cells, as well as the ability of these cells to synthesize such peptides
(Luger and Lotti, 1998).
Substance P (SP)
One

example

is

the

neuropeptide SP (i.e., neurokinin
1) that interacts with the immune
system to instigate the release of
cytokines and growth factors at
sites of injury. It is a highly
conserved 6 kDa member of the
tachykinin family of endogenous
neuropeptides

(Fig.

3)

whose

Figure 3. Alternative splicing of RNA produces
multiple pre-cursors and further processing leads
to mature peptides of the tachykinin family such
as substance P (Siegel et al., 1999).
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undecapeptide sequence is homologous in mouse and human (Hong et al.,
2009). It contains a conserved carboxyl terminal sequence: Arg-Pro-Lys-Pro-GlnGln-Phe-X-Gly-Leu-Met-NH2 (in mammals, X is either Phe or Val) (Brodgen et
al., 2005; Harrison and Geppetti, 2001). Enzymes (i.e., CCAAT/enhancer binding
protein β, Cebpb) post-translationally process inactive preprotachykinin A (PPTA) protein into active SP (Kovács et al., 2006, Siegel et al., 1999).
Expression of SP is widely abundant in both the CNS and PNS (Harrison and
Geppetti, 2001; Schaffer et al., 1998). It is synthesized in the dorsal root ganglia
and travels to the dorsal horn of the spinal cord. From there, SP migrates to the
periphery via afferent sensory neurons. In the brain, moderate amounts are seen
in the hypothalamus with sparse distribution in the thalamus and cortex. Many
neurons in the substantia nigra also contain this neuropeptide.
SP utilizes neurokinin receptor 1 (NK-1R), a G-coupled protein receptor, to
stimulate phosphlipase C (PLC) and thus generate inositol triphosphate (IP3) and
diacylglycerol (DAG). The downstream affects of IP3 and DAG include increasing
cytoplasmic Ca2+ and phosphokinase C (PKC), respectively; both are essential
for vasodilation during inflammation. Receptor stimulation also leads to activation
of mitogen-activated/extracellular signal-related protein kinase (ERK) (Harrison
and Geppetti, 2001).
SP stimulates the production of pro-inflammatory cytokines (e.g., IL-1β, TNFα, IFN-γ, IL-12p40) through activation of transcription factor NFκB, while
diminishing levels of anti-inflammatory IL-10, creating exacerbated states of
disease in BALB/c mice (McClellan et al., 2008). In contrast, SP is also essential
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in tissue repair and has healing properties when administered exogenously
(Hong et al., 2009; Delgado et al., 2005; Muller et al., 2003). However, SPmediated cytokine release and chemoattraction of leukocyte infiltration may not
only aid in healing, but can lead to damage if the infiltrate is left unregulated
(Hong et al., 2009; Chancellor-Freeland et al., 1995). Regulation of this "doubleedged sword" neuropeptide is primarily through enzymatic catabolism and
inactivation by cell surface peptidases [e.g., neutral endopeptidase (NEP)]
(Schaffer et al., 1998).
Stored SP is delivered via nociceptive afferent sensory fibers to wound sites
throughout the body, particularly “areas of immunologic importance” such as the
gastrointestinal and respiratory tracts, as well as the skin (Schaffer et al., 1998).
Another mucosal barrier under the affect of SP is the corneal epithelium; SP
utilizes the ciliary branches of the trigeminal nerve (CN V) for its delivery to the
eye. These fibers join other corneal neurons to form one of the most dense
neuronal networks in the human body (Fig. 1) (Marfurt et al., 2009; Muller et al.,
2003; Jones and Marfurt, 1997).
The cornea is densely innervated with SP-containing nerve terminals (Marfurt
et al., 2009; Muller et al., 2003; Jones and Marfurt, 1997). This makes
understanding SP’s role as a master regulator of infection/inflammation, innate
immunity, immunomodulation, and tissue homeostasis an important goal relevant
to human bacterial keratitis. In this regard (and in light of its dual function
potential) the present work focuses on understanding the role of SP in regulation
of growth factor expression, Toll-like receptor signaling, and its similarity to
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outcome after rapamycin (a regulator of mTOR) treatment in a mouse model of
bacterial keratitis.
Vasoactive Intestinal Peptide (VIP)
Another important neuropeptide in the cornea is VIP, a 28 amino acid
member of the secretin superfamily that has been implicated in the antiinflammatory responses of both the innate and acquired immune system
(Smalley et al., 2009). VIP is delivered to the cornea via efferent parasympathetic
nerve fibers (Muller et al., 2003); it is also produced by corneal endothelial cells
and is present in the aqueous humor of humans and rabbits (Koh et al., 2005).
VIP signals via three receptors: VPAC1 (or VIPR1), VPAC2, and PAC1. VIPR1
on macrophages are the primary effectors through which VIP exerts its effects in
the LPS-stimulated cornea (Szliter et al., 2007).
Our laboratory and others have shown that VIP treatment of susceptible B6
mice improves disease outcome through elevation of anti-inflammatory cytokines
(e.g., IL-10; Szliter et al., 2007) and growth factors (e.g., EGF, HGF, FGF-7;
Jiang et al., 2011), thereby limiting cell-mediated immunity. It also limits
proliferation of macrophages and T-cells (Delgado et al., 2004). Furthermore, the
cornea of resistant BALB/c mice contain more abundant levels of VIP-labeled
neurons than the B6 (Szliter et al., 2007).
The Growth Factors: EGF, HGF/SF, FGF-7/KGF
Growth factors (GF) are instrumental in the evolution and resolution of
inflammation. They are naturally-occurring in the body and facilitate cell-to-cell
communication in order to enhance cell proliferation and migration, essential to
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restoring tissue functionality after injury. In the cornea, they are involved in
homeostasis, wound healing, and development (Wilson et al., 1999).
Epidermal growth factor (EGF)
EGF is produced as a type I transmembrane precursor protein that is cleaved
to a 6 kDa active soluble form. This processing (called “ecto-domain shedding”)
is performed by cell-surface proteases, in particular, the ADAM family of
metalloproteases. Ectodomain shedding is “a crucial step in the control of ligand
availability and receptor activation” (Higashiyama et al., 2007).
EGF binds to EGFR, a 170 kDa member of the ErbB family of tyrosine kinase
receptors that is critical for successful wound healing (Spix et al., 2007). Once
activated, EGFR stimulates the mitogen-activated protein kinase (MAPK) and
phosphoinositidine 3-kinase (PI3K) pathways (Boucher et al., 2010). Under
homeostatic

conditions,

the

availability

of

EGFR

is

controlled

by

its

spatiotemporal expression and ligand shedding.
In the cornea, epithelial cells produce EGF and it acts in an autocrine and
paracrine manner on nearby epithelial cells and stromal fibroblasts. Also, it can
be produced in the lacrimal gland and delivered topically to the corneal surface
via the tear film. EGF functions to maintain corneal epithelial barrier function by
aiding in its repair after injury. This may be critical in the defense of the eye
against pathogens. Moreover, it is integral in the proliferation, differentiation, and
migration of corneal epithelial cells and has been shown to stimulate injuryinduced corneal epithelial wound closure (Tuli et al., 2006; Wilson et al., 1994).
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Hepatocyte growth factor (HGF)
HGF, also known as scatter factor (SF), is a mediator of re-epithelialization; it
influences cell growth, differentiation, and motility (Li and Tseng, 1997). HGF
also has specific functions in mesenchymal-epithelial interactions during
development, angiogenesis, and oncogenesis; it is primarily secreted by cells of
mesenchymal origin (e.g., corneal fibroblasts) and infiltrating PMN (Conway et
al., 2006; Li and Tseng, 1997). It also can be produced by the lacrimal gland and
delivered via the tear film to the eye surface.
At the site of injury, a series of proteases (e.g., hepatocyte growth factor
activator, HGFA) are responsible for cleaving the single-stranded pro-form of
HGF into the active form. In its active form, HGF is structurally unique from other
growth factors with its heterodimeric structure possessing an alpha and beta
chain. Its epithelial receptor, c-met (HGFR) is upstream from the PI3K cell
survival pathway; HGF is the only known ligand for c-met.
Active HGF has been shown to trans-activate EGFR, which is essential in cell
migration (Spix et al., 2007), while EGF itself has been shown to upregulate HGF
(Li and Tseng, 1997). Another modulator of HGF expression is IL-1β, derived
from inflammatory cells and capable of HGF upregulation. TGF-β1 has been
shown to downregulate HGF production by preventing the over-production of
epithelial cells via a negative feedback mechanism (Li and Tseng, 1997).
Fibroblast growth factor 7 (FGF-7)
FGF-7, which is also known as keratinocyte growth factor (KGF), is a member
of the FGF family of growth factors. It shares similar roles with EGF and HGF,
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including paracrine-mediated cell growth, differentiation, and motility. Produced
by stromal fibroblasts of the corneal limbus, it has been detected during wound
closure when the epithelium is being restored. Moreover, FGF-7 mRNA
transcripts have been shown to peak 24 hours post-injury whereas other
cytokines are active earlier (Li and Tseng, 1997). Its distribution in the body is
diverse and not only includes the cornea, but also mammary glands, liver, skin,
and the prostate gland. It signals through FGFR2 that is upstream of the
PI3K/Akt pathway.
Regulation of this growth factor is through intermediate modulators. Chedid et
al. (1994) has shown that FGF-7 is upregulated by the pro-inflammatory cytokine
IL-1β and angiogenic platelet-derived growth factor BB (PDGF-BB). Li and Tseng
(1997) have also demonstrated that, much like HGF, TGF-β1 is a strong
downregulator of FGF-7. In conflicting studies, EGF has been shown to mildly
upregulate (Brauchle et al., 1994) and downregulate (Li and Tseng, 1997) the
FGF-7 transcript.
The PI3K/Akt Pathway
The PI3K/Akt pathway is initiated by growth factors interacting with their
tyrosine kinase receptors (e.g., EGF+EGFR, HGF+c-met). The receptor activates
PI3K that in turn targets the serine-threonine kinase Akt (Franke et al., 1997). Akt
is anti-apoptotic and has a distinct role in cell survival, proliferation, and growth
(Koon et al., 2007). Its downstream target, mTOR, has been shown to interact
with IKK of the TLR4 pathway) by Dan et al. (2008) and others (Madrid et al.,
2001; Ozes et al., 1999). Ultimately, this promotes the phosphorylation and
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translocation of NFκB to the nucleus, causing it to accumulate and bind to target
sequences that enhance the production of pro-inflammatory cytokines and
prevent apoptosis (Dan et al., 2008). This suggests linkage of the GF/PI3K/Akt
and LPS/TLR4/NFκB pathways via mTOR and suggests their putative
interactions that may promote cell survival (Fig. 4).
The Toll-Like Receptor 4 (TLR4) Pathway
TLR are a group of highly conserved transmembrane proteins that are
expressed in a variety of myeloid cells (e.g., macrophages, PMN, T-cells, APC)
and non-myeloid cells (e.g., epithelia, endothelia, and fibroblasts) (Redfern et al.,
2010; Albiger et al., 2007). Their primary function is pathogen recognition, but
recent studies have implicated TLR in the stimulation of localized production of
antimicrobial agents such as human beta defensin-2 (hBD-2) (Redfern et al.,
2010). To date, thirteen murine (and ten human) TLR have been identified; TLR4
is the most extensively studied and recognizes a variety of ligands, chief among
them is LPS from Gram-negative bacteria such as P. aeruginosa (Albiger et al.,
2007). The TLR4 receptor pathway is activated by the interaction of host cell
membrane GPI-anchored CD-14 and LPS present on the surface of the
bacterium. After which, LPS is transferred to soluble MD-2 (LY96) to activate
TLR4. Upon ligand binding, TLR4 dimerizes and its cytoplasmic TIR domains
interact with adaptor molecules. This initiates signaling through both MyD88dependent and MyD88-independent pathways, leading to pro-inflammatory
cytokine production.
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The MyD88-dependent pathway uses MyD88 and TIR-associated protein
(TIRAP), while the independent pathway utilizes TIR domain-containing adaptor
protein-inducing molecule 1 (TICAM-1) and TRIF-related adaptor molecule
(TRAM), also called TICAM-2. Recent studies have shown that TIRAP in
particular is required for signaling by TLR4 (Albiger et al., 2007). Figure 4
illustrates a putative interaction for molecules of the MyD88-dependent and
related pathways.

Figure 4. The proposed interaction between the MyD88-dependent LPS/TLR4/NFκB and
GF/PI3K/Akt pathways.

The MyD88-dependent pathway stimulates IL-1R-associated kinase 4 (IRAK4) that in turn activates IRAK-1 that then associates with TNFR-associated factor
6 (TRAF-6). TRAF-6 activates transforming growth factor (TGF)-β-activating
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kinase 1 (TAK-1), which phosphorylates IKK-β, an enzyme that acts as the
catalytic subunit of the IKK complex (Dan et al., 2008). This causes the
dissociation and degradation of the IκB subunit from the IKK complex allowing for
the translocation of NFκB to the cell nucleus (Sizemore et al., 2002). This
translocation initiates the production of pro-inflammatory cytokines (e.g., IL-1β,
IL-12p40, and TNF-α.
The MyD88-independent pathway (not shown) signals to induce the
production of interferons (e.g., IFN-γ). Interferons respond to infection by viruses,
inhibiting their replication in a host cell. This pathway requires TRIF and its
adaptor molecule TRAM. TRIF interacts with receptor-interacting protein 1 (RIP1) and TRAF-6 inducing the nuclear translocation of NFκB. Also, TRIF
associates with TRAF family members-associated NFκB activator (TANK)
binding kinase (TBK1). This leads to the phosphorylation of IRF-3 and IRF-7
allowing for their nuclear translocation and induction of IFN-γ and other
interferons (Albiger et al., 2007).
Regulation of these pathways is essential to maintain the body’s endogenous
bacterial colonies and recognition of invaders without causing deleterious
inflammation. Control of a given TLR is primarily through modulation of its cellular
localization. Selective recruitment and/or inhibition of the adaptor molecules can
also serve to regulate the pathways. Lastly, negative regulation along the
pathway

works

to

control

it:

phosphorylation/degradation

of

proteins,

sequestration, and the interaction of pathway members with inhibitory molecules.
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Mammalian target of rapamycin (mTOR)
mTOR is the target of a diverse array of microbes, growth factors, hormones,
and amino acids that elicit a host innate immune response. mTOR itself is a
serine-threonine kinase that also mediates cell growth and proliferation, ribosome
biogenesis, and cytoskeletal reorganization (Thomson et al., 2009; Yang and
Guan, 2007). It is contained within two functional complexes: mTORC1 and
mTORC2 and is active when complexed with Raptor, mLST8, and PRAS40
(forming mTORC1), or when complexed with Rictor, mLST8, and Sin1 (forming
mTORC2) (Thomson et al., 2009; Yang and Guan, 2007).
mTORC1 alone is sensitive to inhibition by the macrolide antibiotic rapamycin
that blocks the formation of the complex described above. Clinically, rapamycin is
used as an immunosuppressant in allogeneic transplantation. However, recent
evidence has shown that if used in this manner, it has specific inflammatory side
effects, including: fever, anemia, and severe cases of glomerulonephritis
(Säemann et al., 2009). Moreover, concern is mounting against the use of
rapamycin because adverse side effects also have included resistance to
antimicrobial therapy (Weiner et al., 2007).
mTOR is an upstream regulator of immunoregulatory cytokines (e.g., IL-10) in
several infectious disease models (Baker et al., 2009; Weichhart et al., 2008),
including P. aeruginosa-induced keratitis (Foldenauer et al., 2012, submitted for
publication). It is also implicated in both growth and inflammatory pathways
(Baker et al., 2009). Previous work also has shown that mTOR plays a role in
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regulating the IL-10/IL-12 axis in LPS stimulated macrophages and controls the
innate immune response (Cheekalta et al., 2012).
Apoptosis
Tight regulation of the balance between programmed cell death, or apoptosis,
and cell survival, as well as, the timing of apoptotic events, is critical to immune
defense; persistence of apoptotic cells can worsen disease outcome (Zhou et al.,
2008; Ren and Savill, 1998). Apoptotic cells can lose the ability to regulate cell
volume that can lead to rupture and release of enzymes that are potentially
damaging to surrounding tissue. An in vitro study where apoptosis was blocked
with colchicine reported PMN undergoing secondary necrosis in which large
quantities of elastase was released (Ren and Savill, 1998). Our laboratory
determined that, in susceptible C57BL/6 mice, PMN apoptosis is delayed and
this contributes to inflammation-induced tissue damage in the cornea.
Furthermore, administration of pro-inflammatory SP to resistant BALB/c mice (in
which apoptosis is earlier, protecting against disease pathogenesis), delays
apoptosis and leads to worsened disease (Zhou et al., 2008).
Impact and Significance
The annual rate of microbial keratitis in the US is 25,000-30,000 cases with
an estimated cost of $15-$30 million dollars (Kharti et al., 2002). It is most
frequently associated with complications of contact lens usage and P. aeruginosa
accounts for approximately 70% of cases (Schein et al., 1989).
Research in this area addresses a major objective of the Corneal Diseases
Program (from The National Plan for Eye and Vision Research): to “investigate
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corneal infectious processes and immunological responses… to develop
treatments to reduce keratitis and prevent blindness.”
The impact of the neuropeptides SP and VIP on growth factors and Toll-like
receptors in the cornea will provide insight and direction in the quest for
therapeutics to regulate corneal infection and other inflammatory pathologies.
Moreover, modulation of mTOR levels (downstream of SP) in the human cornea
has largely gone unexplored and may afford another avenue to combat ocular
disease. The goal of this dissertation was to test these hypotheses:
1. SP modulates growth factors during microbial keratitis, worsening disease.
2. Inhibition of mTOR (via rapamycin) decreases IL-10 during microbial
keratitis, which dysregulates inflammation in the cornea.
3. During microbial keratitis, VIP is not required for expression of growth
factors or their receptors, but is critical for their regulation.
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CHAPTER 2: Substance P affects growth factors in Pseudomonas
aeruginosa-infected mouse cornea.
ABSTRACT
Purpose: This study analyzed the influence of SP on growth factors related to
wound healing in mice in the presence of infectious keratitis.
Methods: Naturally resistant mice were injected intraperitoneally with SP or
phosphate buffered saline (PBS), infected with Pseudomonas aeruginosa, and
corneal mRNA levels of growth factors and apoptosis genes tested. Enzymelinked

immunosorbent

assay

(ELISA)

determined

protein

levels,

while

immunohistochemistry tested distribution, macrophage phenotype, and cell
quantitation. In vitro, macrophages were stimulated with lipopolysaccharide
(LPS) + SP and mRNA levels of pro- and anti-inflammatory cytokines and
apoptosis genes tested.
Results: After SP, epidermal growth factor (EGF) mRNA and protein levels were
disparately regulated early, with no differences later in disease. Hepatocyte
growth factor (HGF) and fibroblast growth factor-7 (FGF-7) mRNA and protein
levels were increased after SP treatment. Enumerating dual-labeled stromal cells
revealed no difference between SP- vs. PBS-treated groups in the percent of
EGF-labeled fibroblasts or macrophages, but significant increases in both HGFand FGF-7 labeled cells. Type 2 (M2) macrophages and caspase-3 mRNA levels
were decreased, while B cell lymphoma-2 (Bcl-2) mRNA expression was
increased after SP treatment. In vitro, mRNA levels of several pro-inflammatory
cytokines and Bcl-2 were elevated, while transforming growth factor (TGF)-β was
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decreased after macrophage stimulation with SP (+ LPS) over LPS alone. (Mice:
n=105 control; 105 experimental).
Conclusions: These data show that treatment with SP in infectious keratitis
elevates growth factors, but also adversely effects disease by enhancing the
inflammatory response and its sequelae.
INTRODUCTION
One of the most common isolates from patients with microbial keratitis is
Pseudomonas aeruginosa (P. aeruginosa) (Pachigolla et al., 2007). It is classified
as an opportunistic, Gram-negative bacterium that causes keratitis in patients
who are immuno-compromised and in extended wear contact lens users
(Wilhelmus, 1995). The infection is rapid and triggers a host immune response
that can lead to vision loss (Lyczak et al., 2000).
Previous experimental studies using BALB/c [T helper cell type 2 (Th2)
responder, resistant] and C57BL/6 [T helper cell type 1 (Th1) responder,
susceptible] mice, have characterized their responses to P. aeruginosa infection
and shown that C57BL/6 mice undergo more severe disease with corneal
perforation when compared to BALB/c mice (Hazlett et al., 2000). These studies
have examined the role of the host inflammatory response, including the
production of cytokines and chemokines and the participation of various cells
[e.g., macrophages (McClellan et al., 2003), neutrophils (Kernacki et al., 2000), T
lymphocytes (Kwon and Hazlett, 1997), and natural killer (NK) cells (Lighvani et
al., 2005)] in animal models of the disease. In macrophages, gene expression
profiling has shown that Gram-negative bacteria induce transcriptional activation
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of a common host response that induces genes in these cells expressing a type
1 macrophage (M)1 program (Benoit et al., 2008). M1 polarized cells, prototypical
in Th1 responder strains of mice such as C57BL/6 (Mills et al., 2000), are
characterized by production of Interleukin (IL)-12, tumor necrosis factor (TNF)α, macrophage inflammatory protein-2 (MIP-2), and high levels of nitric oxide
synthase 2 (NOS2) (Joshi et al., 2008; Mantovani et al., 2002). Excessive or
prolonged M1 polarization can lead to tissue injury and contribute to
pathogenesis, as shown in previous work from this laboratory (Hazlett et al.,
2010). In contrast, Th2 responder mice (BALB/c) possess a higher population of
alternatively activated macrophages, designated M2 cells, that produce antiinflammatory mediators such as IL-10, IL-1 receptor antagonist (ra), and type II
IL-1 decoy receptor (Mantovani et al., 2002), that upregulate production of
arginase 1 (Mills et al., 2000) and are critical to innate immunity and disease
resolution (Hazlett et al., 2010).
An important role of the innate immune system (as well as general wound
healing) in the cornea is the maintenance of homeostasis. Furthermore, in recent
years, the link between the immune system and neuropeptides has been well
established in numerous systems (Zhang et al., 2006; Luger et al., 1998),
including models of corneal infection (McClellan et al., 2008; Szliter et al., 2007).
Evidence for this link includes the presence of neuropeptide receptors on and the
proximity of neuronal terminals to leukocytic cells (i.e., macrophages), as well as
the ability of these cells to synthesize peptides (Luger et al., 1998). One such
peptide is SP that interacts with the innate immune system to stimulate the
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release of cytokines and augment inflammation in various experimental models
(Chauhan et al., 2011; Sahbaie et al., 2009; Lucey et al., 1994; Payan, 1989).
SP is an 11-amino acid member of the tachykinin family of neuropeptides that
stimulates the production of pro-inflammatory cytokines [e.g., IL-1β, TNF-α, and
interferon-gamma (IFN-γ)] through activation of transcription factor nuclear factor
kappa-light-chain-enhancer of activated B cells (NFκB), creating exacerbated
states of disease (Sun et al., 2008). In contrast, in non-infectious wound or
trauma models, it is thought to be essential in tissue repair and has healing
properties when administered exogenously (Muangman et al., 2009; Hong et al.,
2009; Delgado et al., 2005). Moreover, SP-mediated cytokine release and the
chemo-attraction of infiltrating leukocytes (neutrophils, macrophages) aids in
healing, but can cause damage if left unregulated (Hong et al., 2009; Sun et al.,
2008), due in part to the anti-apoptotic effects of SP (Zhou et al., 2008). It has
been shown that levels of SP are low in BALB/c mice and, when the
neuropeptide is administered exogenously via intraperitoneal injection, corneal
disease is worsened with increased cellular infiltrate, bacterial number, proinflammatory cytokines/chemokines, NFκB activation, and reduced levels of antiinflammatory cytokines, all of which result in corneal perforation (McClellan et al.,
2008; Hazlett et al., 2007).
Important components in corneal wound healing after non-infectious trauma
are growth factors, naturally occurring peptides that facilitate cell-to-cell
communication, enhance cell proliferation and migration, and tissue function. Of
interest are three classic growth factors: epidermal growth factor (EGF),
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hepatocyte growth factor (HGF) and fibroblast growth factor-7/keratinocyte
growth factor (FGF-7/KGF). Their presence and function in non-infectious wound
healing in the cornea has been firmly established (Carrington and Boulton, 2005;
Repertinger et al., 2004; Wilson et al. 1999), however, little information is
available regarding these growth factors in a model of corneal infection (Jiang et
al., 2011).
Thus the purpose of the current study was to test the regulatory role of SP on
growth factor production in BALB/c mice, whose cornea normally does not
perforate after infection (Hazlett et al., 2000). We provide insight into the dual
role of SP in this model of bacterial infection. We show that SP has a dual role in
this model of bacterial infection, unexpectedly upregulating growth factor
production. This was accompanied by macrophage specific upregulation of proinflammatory cytokines, downregulation of anti-inflammatory cytokines and
upregulation of anti-apoptotic genes, as well as a decrease in arginase-producing
macrophages (M2 cells), important in stromal healing in these mice (Mills et al.,
2000). All of these lead to worsened disease, despite the stimulatory effects on
growth factor production and contraindicate clinical use of SP in cornea to
promote wound healing, if an infection is present or suspected.
MATERIALS AND METHODS
Mice. Female, 8-week-old, immunologically mature, BALB/c mice were
purchased from The Jackson Laboratory (Bar Harbor, ME) and housed in
accordance with the National Institutes of Health guidelines. Humane animal care

27
conformed to the Association for Research in Vision and Ophthalmology (ARVO)
Statement for the Use of Animals in Ophthalmic and Vision Research.
Bacterial culture and infection. P. aeruginosa cultures (strain 19660;
purchased from the American Type Culture Collection, Manassas, VA) were
grown in peptone tryptic soy broth as described by Hazlett et al. (1987). The
central cornea of each anesthetized mouse was scarred with a sterile needle and
a 5 µL inoculum (1X106 CFU/µL) applied.
SP treatment. BALB/c mice were anesthetized and injected intraperitoneally with
100 µL of sterile phosphate buffered saline (PBS) containing 15 µM SP (SigmaAldrich, St. Louis, MO) each day from the day before infection (d = -1) to 5 days
after infection (for mRNA) or 7 days (for protein). Controls were similarly injected
with sterile PBS and disease was graded after infection on days 1, 3, 5, and 7,
using a clinical score system described by Hazlett et al. (1987).
Real-time reverse transcriptase polymerase chain reaction (RT-PCR). Mice
were sacrificed and normal and infected corneas from SP- and PBS-treated mice
(n = 5/treatment/time=30 mice) were removed (1, 3, and 5 days). Each cornea
was briefly stored in RNA STAT-60™ (Tel-Test, Friendswood, TX) at -20ºC
before processing (McClellan et al., 2008).
To assess transcriptional changes, mRNA levels of EGF, HGF, FGF-7,
caspase-3, and B cell lymphoma-2 (Bcl-2) were tested by real-time RT-PCR
(MyiQTM Single Color Real-Time PCR Detection System; Bio-Rad, Hercules, CA).
Real-Time SYBR® Green/Fluorescein PCR Master Mix (Bio-Rad) was used for
the PCR reaction with primer concentrations of 5 µM, as described previously by
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McClellan et al. (2008). Fold differences in gene expression were calculated after
normalization with β-actin. Growth factor primer pair sequences used for realtime RT-PCR were purchased from SABiosciences (Frederick, MD). Other
primers for caspase-3, Bcl-2, and β-actin have been described previously by
Zhou et al. (2008).
Enzyme linked immunosorbent assay (ELISA). After SP or PBS treatment,
translational effects (protein levels) for SP, IL-1β, and the growth factors were
determined using ELISA kits (R&D Systems, Minneapolis, MN) as described
previously by McClellan et al. (2008). SP and IL-1β protein levels were
determined from individual (SP- or PBS-treated) normal and infected BALB/c
corneas (n = 5/group/treatment/assay=20 mice) and uninfected duodenum (taken
from 10 corneally-infected mice) at 3 days after infection. The assay sensitivity
for SP was 16.8 – 43.8 pg/mL and <3.0 pg/mL for IL-1β.
For the growth factors, mice were sacrificed and individual (SP- or PBStreated) normal and infected (1, 5, and 7 days) corneas (n=5/treatment/time=30
mice) were harvested. Corneas were individually homogenized in sterile PBS
containing 0.1% Tween® 20 and a protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, IN) as described previously by McClellan et al. (2008).
The reported sensitivity of the EGF assay was 0.32 – 1.64 pg/mL. Sensitivity for
the HGF and FGF-7 assays was determined by comparison to a standard curve
concentration (R&D Systems). A human FGF-7 ELISA assay kit was used since
a commercial murine kit was not available; others have established its
effectiveness for murine samples (Pedchenko et al., 2000).
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Immunostaining. Normal and P. aeruginosa-infected (5 days) eyes were
enucleated from SP- or PBS-treated BALB/c mice (n=5/treatment/growth
factor=30 mice), embedded in optimal cutting temperature (OCT) compound, and
snap frozen in liquid nitrogen. Sections (10 µm) were cut, fixed in acetone, and
incubated in blocking agent as described previously by McClellan et al. (2008).
Sections were incubated with individual primary antibodies (goat anti-mouse
EGF/HGF/FGF-7; 1:10; R&D Systems) in blocking agent for 1 hour, rinsed with
buffer, and incubated for another hour with Alexa Fluor 546 donkey anti-goat IgG
secondary antibody [(1:1500; Molecular Probes, Eugene, OR) in 0.01M Tris-HCl].
In another experiment (n=5/treatment/group=60 mice), sections were incubated
with antibodies specific for growth factors and macrophage-specific primary
antibody rat anti-mouse F4/80 (1:100; Santa Cruz Biotechnologies, Inc., Santa
Cruz, CA) or fibroblast-specific rat anti-mouse ER-TR7 (1:50; Santa Cruz
Biotechnologies, Inc.). Then, appropriate secondary antibodies were applied:
Alexa Fluor 546 goat anti-rat IgG (1:1500; Molecular Probes) and cyanine dye 5
conjugated donkey anti-rat (Jackson Immunoresearch, West Grove, PA).
In the next experiment (n=5/treatment/group=20 mice), sections were
incubated with macrophage specific primary antibody (F4/80) followed by rabbit
anti-mouse NOS2 (M1 phenotype) or arginase (M2 phenotype) (1:200; Santa
Cruz Biotechnologies, Inc.). Then, secondary antibodies (in 0.01M Tris-HCl) were
applied: Alexa Fluor 546 goat anti-rat IgG (1:1500; Molecular Probes) and Alexa
Fluor 633 goat anti-rabbit IgG (Molecular Probes), respectively.
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All sections were incubated with a nuclear acid stain (SYTOX® Green,
1:20,000; Lonza, Walkersville, MD) and controls for each of the experiments
were treated the same, with exception that each primary antibody was replaced
by the same host species IgG. Digital images were captured on a confocal laserscanning microscope (TCS SP2, Leica Microsystems, Exton, PA).
Semi-quantitative cell counts. Three representative confocal micrographs
(208X magnification) per group were analyzed essentially as described by
Sensoo and Joyce (2000). Briefly, the total number of either F4/80 or ER-TR7
positive cells were counted in four 150 µm2 areas of each micrograph (12
areas/group). Dual labeled cells (positive for each growth factor and either
specific label above) were enumerated, averaged, and expressed as a percent of
the total number of F4/80 or ER-TR7 positive cells. In a separate experiment,
stromal F4/80-labeled macrophages positive for NOS2 (M1 cells) or arginase
(M2 cells) were counted similarly.
Macrophage culture and real-time RT-PCR. BALB/c mice (n=10 mice) were
injected intraperitoneally with 1 mL of a 3% Brewer’s thioglycollate medium
(Becton-Dickinson, Sparks, MD) to stimulate macrophages into the peritoneal
cavity and to increase yield (Fortier, 1994). Seven days later, macrophages were
harvested from the collected peritoneal fluid, and centrifuged at 1000 rpm for 10
minutes. The remaining pellet was re-suspended with 10 mL of DMEM media
(Invitrogen, Carlsbad, CA) and a 10 µL aliquot was stained with Trypan Blue dye
(1:1; Invitrogen) for cell counts with a hemacytometer. Cells were seeded in 12well plates at a density of 3 x 106 cells/well (n=3 wells/group) and incubated at
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37ºC for 1 hour. Media was removed and adherent cells stimulated as follows: 10
µL of 1 µg/mL lipopolysaccharide (LPS; L9143 from P. aeruginosa, serotype 10;
Sigma-Aldrich) + 1 µL of 1 x 10-9 M or 1 x 10-12 M SP (Bowden et al., 1994)
(Sigma-Aldrich), SP alone, or media (control) to a total volume of 1 mL and
incubated for 18 hours at 37ºC. Then, cells and media were removed from the
wells and centrifuged for 5 minutes at 7300 rpm. Pellets were reconstituted in
RNA STAT-60® (Tel-Test) and processed for mRNA as described above. IL-1β,
IL-18, MIP-2, TNF-α, NFκB, and transforming growth factor (TGF)-β mRNA
levels were tested as described above using previously published primer
sequences (McClellan et al., 2008).
Statistical analysis. An unpaired, two-tailed Student’s t-test was used to
determine the statistical significance of the real-time RT-PCR, ELISA, and cell
counts. Data were considered significant at p<0.05. All experiments were
repeated at least once to ensure reproducibility and data from a representative
experiment are shown as mean + standard error of the mean (SEM).
RESULTS
ELISA analysis of SP and IL-1β. To determine if SP injection elicited systemic
effects, individual normal and infected corneas and normal duodena were
harvested 3 days after infection and protein levels for SP and IL-1β assayed (Fig.
5A, B). No significant difference in SP levels was detected in either the normal
cornea or duodenum after SP vs. PBS treatment. However, in the infected
cornea, SP vs. PBS treatment increased local SP levels (p=0.03; Fig. 5A). IL-1β
protein (Fig. 5B) was undetectable in the normal cornea in either SP- or PBS-
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treated mice. However, after 3 days of infection, significantly (p=0.04) increased
levels of the cytokine were seen in SP- over PBS-treated samples. No
differences were detected between groups in the duodenum (Fig. 5B).
Real-time RT-PCR and ELISA analysis of the growth factors. Figure 6 shows
corneal mRNA (A-C) and protein (D-F) levels of the growth factors after SP vs.
PBS treatment. At 1 day after infection, EGF mRNA levels were increased
(p<0.0001) in the cornea of SP- vs. PBS-treated mice (Fig. 6A), however, there

Figure 5. ELISA analysis of SP (A) and IL-1β (B) protein levels. Samples are taken from normal
cornea and at 3 days post-infection and duodena, harvested 3 days post–infection from corneally
infected mice. Samples compare mice injected with Substance P (SP) vs. Phosphate buffered
saline (PBS).

was no difference between groups in the normal uninfected cornea or at 5 days
after infection. EGF protein levels (Fig. 6D) were significantly decreased in the
SP- vs. PBS-treated group at 1 day after infection (p=0.0001), but no difference
between groups was detected in the normal or after 5 or 7 days of infection.
SPtreatment resulted in a significant increase in HGF mRNA expression (Fig. 6B)
in the normal cornea (p=0.006) and at 5 days after infection (p=0.02), when
compared to PBS controls. No difference was detected at 1 day after infection
between these groups. HGF protein (Fig. 6E) was significantly increased in
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normal cornea and at 1, 5, and 7 days of infection after SP treatment (p<0.0001,
p=0.003, p<0.0001, p<0.0001, respectively). FGF-7 mRNA expression (Fig. 6C)
was significantly increased at 5 days after infection (p=0.03) following SP
treatment, with no difference between groups in the normal cornea or at 1 day of
infection. FGF-7 protein levels (Fig. 6F) were significantly increased after SP
treatment after infection (1, 5, and 7 days) (p<0.0001 for each) with no difference

Figure 6. Corneal growth factor mRNA (A, B, C) and protein (D, E, F) levels after treatment with
PBS vs. SP. Samples are taken from normal cornea and at 1, 5 and/or 7 days post-infection from
corneally infected mice. Samples compare mice injected with Substance P (SP) vs. Phosphate
buffered saline (PBS).
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between groups in the normal cornea.
Immunofluorescent staining. Qualitative differences in immunostaining for the
growth factors (red) were detected between SP- vs. PBS-treated groups (Fig. 7)
after infection (5 days). Similar EGF staining was observed primarily in the
epithelium in both treatment groups (Fig. 7A, B). HGF staining was observed in
the epithelium and stroma, but was more intense in the SP- (Fig. 7D) vs. PBS(Fig. 7C) treated group. More intense staining also was seen for FGF-7 after SP
(Fig. 7F) vs. PBS (Fig. 7E) treatment. Representative same host species IgG
controls are shown for the PBS- (Fig. 7G) and SP- (Fig. 7H) treated groups.
Dual-immunostaining was used to investigate the cellular origin of the growth
factors. Cells were stained for an individual growth factor and either fibroblast
(ER-TR7) or macrophage (F4/80) markers 5 days after infection. The results are
shown in Figures 8 and 9, respectively. There was no qualitative difference in the
number of dual labeled cells that stained positively for EGF (red) and ER-TR7
(blue) (Fig. 8A, B) or EGF (red) and F4/80 (blue) (Fig. 9A, B) in the PBS- vs. SPtreated groups (merged images shown). However, SP-treated mice had
qualitatively more fibroblasts and macrophages that stained positively for HGF
(Fig. 8D and 9D) and FGF-7 (Fig. 8F and 9F) than after PBS treatment (Fig. 8C
and 9C; Fig. 8E and 9E, respectively; merged images shown). Insets (Fig. 8D, F
and 9D, F) are shown at greater magnification for dual labeled fibroblasts (Fig. 8)
and macrophages (Fig. 9). Representative same host species IgG controls are
shown for the PBS- (Fig. 8G and 9G) and SP- (Fig. 8H and 9H) treated groups.
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Figure 7. Merged images of immunohistochemistry of the growth factors (red) in PBS- vs. SPtreated BALB/c cornea 5 days after infection. Samples compare mice injected with Substance P
(SP) vs. phosphate buffered saline (PBS). Nuclei are labeled with SYTOX® Green (green).
Magnification=155X; Bar=80 µm.
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Figure 8. Merged images of dual-immunostaining for the growth factors (red) and fibroblasts (ERTR7, blue) in the BALB/c cornea at 5 days after infection. Samples compare mice injected with
Substance P (SP) vs. Phosphate buffered saline (PBS). Nuclei are labeled with SYTOX® Green
(green). Magnification=208X; (Insets=360X); Bar=40 µm.
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Figure 9. Merged images of dual-immunostaining for the growth factors (red) and macrophages
(F4/80; blue) in BALB/c cornea at 5 days of infection. Samples compare mice injected with
Substance P (SP) vs. Phosphate buffered saline (PBS). Nuclei are labeled with SYTOX® Green
(green). Magnification=208X; (Insets=360X); Bar=40 µm.
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Semi-quantitative cell counts. To confirm the qualitative dual-immunostaining
data, semi-quantitative cell counts were done 5 days after infection (Fig. 10). The
percentage of dual labeled, EGF-positive fibroblasts and/or macrophages
(expressed as a percent of total fibroblast or macrophage labeling) were not
significantly different between the SP- vs. PBS-treated groups (Fig. 10A).
However, a significant increase in dual labeled HGF-positive fibroblasts
(p<0.0001) and macrophages (p<0.0001) and dual labeled FGF-7-positive
fibroblasts (p<0.0001) and macrophages (p<0.0001) (expressed as a percent of
total fibroblast or macrophage labeling) was seen in the SP- vs. PBS-treated
controls (Fig. 10B, C).

Figure 10. Semi-quantitative cell counts compared the percentage of growth factor-positive cells
to the total number of positively immunostained fibroblasts (ER-TR7) or macrophages (F4/80) in
the stroma of the infected cornea (same mice as in Figure 7) with or without SP treatment at 5
days after infection. Samples compare mice injected with Substance P (SP) vs. Phosphate
buffered saline (PBS).

Macrophage phenotype and cell counts. Dual-immunostaining also was
used to test whether SP treatment affected macrophage polarization in the
stroma of the infected cornea at 5 days after infection and the data are shown in
Figure 11. NOS2-positive (blue), M1 macrophages (red) were detected (merged
image shown) in corneas in mice treated with PBS (Fig. 11A) or SP (Fig. 11B)
and appeared similar. Arginase-positive (blue), M2 macrophages (red) were also
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detected (merged image shown) in the infected stroma of PBS- (Fig. 11C) and
SP- (Fig. 11D) treated mice, but appeared qualitatively decreased in the SP
group. Representative same host species IgG controls are shown for the PBS(Fig. 11E) and SP- (Fig. 11F) treated groups. At 5 days after infection,
macrophages

Figure 11. Merged images of dual-immunostaining for M1 type macrophage (nitric oxide
synthase-2 positive, blue) (A, B) or M2 type macrophage (arginase positive, blue) (C, D) F4/80
(red-labeled) macrophages at 5 days after infection. Samples compare mice injected with
Substance P (SP) vs. Phosphate buffered saline (PBS). Nuclei are labeled with SYTOX® Green
(green). Magnification=208X; Bar=40 µm.
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that were either arginase- or NOS2-positive were quantitated and expressed as a
percentage of total F4/80-positive macrophages, essentially as described above.
The data are shown in Figure 12. There was no significant difference between
treatment groups in the percentage of M1 macrophages, however, a significant
(p=0.003) decrease in the percent of M2-labeled cells was seen after SP vs. PBS
treatment.

Figure 12. Semi-quantitative cell counts of M1 and M2 macrophages. Samples compare mice
(same mice as in Figure 7) injected with Substance P (SP) vs. Phosphate buffered saline (PBS).

Real-time RT-PCR of macrophage cytokines. Since SP decreases the number
of M2-positive cells with no difference in the M1 cell population, we next tested its
effects in vitro on macrophage production of pro- (e.g., MIP-2, TNF-α, NFκB, IL1β, IL-18; Fig. 13A-D, F) and anti-inflammatory (TGF-β; Fig. 13E) molecules to
determine if, in addition to modulating growth factors, SP enhances the proinflammatory cytokine pathway in these cells.
The data show that the effects of SP necessitated the presence of LPS and
SP alone did not give similar effects. Specifically, after 18 hours of stimulation,
SP (10-9 M and 10-12 M) + LPS significantly increased macrophage mRNA levels
of MIP-2 (Fig. 13A; p=0.002 and p=0.001), TNF-α (Fig. 13B; p=0.03 for both),
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NFκB (Fig. 13C; p=0.04 and p=0.02), and IL-1β (Fig. 13F; p=0.002 and p=0.02),
while SP + LPS decreased TGF-β (Fig. 13E; p=0.03 and p=0.04) compared to
stimulation with LPS alone. Both concentrations of SP (in the presence of LPS)
elevated IL-18 mRNA levels, but this was significant only at the higher
concentration of SP (10-9M) (Fig. 13F; p=0.02). Control wells were incubated with
media alone.
Real-time RT-PCR for Bcl-2 and caspase-3. Since SP also has been shown to
delay apoptosis in vivo (Zhou et al., 2008) resulting in a persistence of infiltrating
neutrophils, apoptotic genes were measured in elicited BALB/c macrophages
stimulated with LPS + SP (10-9 M and 10-12 M). Anti-apoptotic Bcl-2 (Fig. 14) was
significantly increased after stimulation with LPS plus either concentration of SP
(p<0.0001 and p=0.02) compared to LPS treatment alone. Levels of proapoptotic caspase-3 were below the level of detectability in the macrophage
samples (data not shown).
To substantiate the above in vitro data, corneal samples were used to probe
for Bcl-2 and caspase-3. In the normal cornea and at 1 and 5 days after infection
(Fig. 15A), there was a significant increase in Bcl-2 mRNA (p=0.003, p=0.03,
p=0.03) with no difference at 3 days of infection after SP vs. PBS treatment.
Caspase-3 was detectable in cornea (Fig. 15B) and was decreased in the normal
uninfected SP- vs. PBS-treated group and after 5 days of infection. (p<0.0001
and p<0.0001). No significant change was seen at days 1 or 3 after infection.
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Figure 13. In vitro mRNA expression of pro- and anti-inflammatory cytokines in macrophages.
Samples compare stimulation with LPS + Substance P (SP) (at two concentrations), SP alone,
and media (control). (n=10 mice)
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Figure 14. In vitro mRNA expression of an anti-apoptotic gene in macrophages. Samples
compare stimulation with LPS + Substance P (SP) (at two concentrations), SP alone, and media
(control).

Figure 15. (A, B) mRNA expression of apoptotic-associated genes in cornea. Samples are taken
from normal cornea and at 1, 3, and 5 days post-infection. Samples compare mice injected with
Substance P (SP) vs. Phosphate buffered saline (PBS).
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DISCUSSION
SP regulates numerous aspects of immune function in that it can either
potentiate damage or promote healing (Hong et al. 2009; Muangman et al., 2009;
Sahbaie et al., 2009; Sun et al., 2008; Zhou et al. 2008; Delgado et al. 2005).
Hong et al. (2009), characterized SP as an “injury-inducible factor” that acts early
in the repair process after wounding, enhancing fibroblast proliferation, with a
similar function after burn injury (Jing et al., 2009). In contrast, SP has been
shown to enhance keratitis in the P. aeruginosa-infected BALB/c mouse cornea
resulting in rapid influx of neutrophils into the site of infection and delaying their
apoptosis (McClellan et al., 2008; Zhou et al., 2008). Despite these documented
effects, that study did not determine whether systemic effects of intraperitoneal
injection of SP played a role in these events (McClellan et al., 2008). Therefore,
in the current work, we similarly tested and established that injection of SP did
not induce systemic effects and that significantly elevated levels of the
neuropeptide were observed only in the infected cornea, and not the duodenum
(a peripheral organ site tested). To confirm these results, we also tested levels of
IL-1β in both sites and found elevated levels of the cytokine only in the infected
cornea, with no differences seen in the duodenum. Together, these data provide
evidence that there is no detectable systemic effect following intraperitoneal
injection of SP in this model. Thus, current work was able to reasonably test the
hypothesis that a contributing factor of enhanced disease in the cornea after SP
injection results from a decrease in growth factor production.
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Growth factors are instrumental in the evolution and resolution of
inflammation.

They

are

naturally-occurring

and

facilitate

cell-to-cell

communication in order to enhance cell proliferation and migration, essential to
restoring tissue functionality after injury (Edwards et al., 2009; Klenker and
Sheardown, 2004; Wilson et al., 2001; Imanishi et al., 2000; Wilson et al., 1999).
Regarding growth factors and regulation by SP, studies have demonstrated that
SP has angiogenic properties, including increasing vascular endothelial growth
factor-A production by epidermal granulocytes (Kohara et al., 2010) and inducing
growth of vascular endothelial cells into the cornea (Ziche et al., 1990). Topical
administration of SP and insulin-like growth factor-1 (IGF-1) to the cornea after
non-infectious injury has been shown to synergistically facilitate epithelial
migration during wound closure (Nakamura et al., 1997). To date, however,
information regarding SP regulation of growth factors known to be important in
non-infectious wound healing (including EGF, HGF, and FGF-7/KGF) is not
available in the infected cornea.
For EGF, Lai et al. (2002) provided evidence that the spatiotemporal
expression of elevated EGF paralleled increased SP immunoreactivity in skin,
while damage to SP-positive neurons decreased EGF levels, worsening disease
outcome. In contrast, the current study found that after SP injection, decreased
protein levels for EGF occurred early (1 day after infection), despite elevated
levels of mRNA at a similar time. Later in disease, no difference in either mRNA
or protein levels of EGF was observed between groups. Since previous studies
on EGF have linked elevated levels of the growth factor with proliferation,
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migration, and differentiation of epithelial cells (Wilson et al., 1999), it appears
difficult to conclude that the early (but not later in disease) decrease in EGF
protein levels contributes directly to increased disease severity, despite our
prediction.
Another growth factor, HGF, is a potent factor in epithelial cell and
keratinocyte proliferation and motility in the cornea (Zelenka and Arpitha, 2008;
Imanishi et al., 2000; Wilson et al., 1994) and other tissues (Li-Juan et al., 2009).
In this regard, primary corneal epithelial cells were treated in vitro with
exogenous HGF that induced marked cellular proliferation (Wilson et al., 1993).
In another in vitro study, HGF treatment enhanced the migration, growth, and
DNA synthesis of human keratinocytes (Matsumoto et al., 1991). The current
study unexpectedly found that after injection of SP, HGF mRNA and protein
levels are elevated up to 7 days after infection. Immunostaining and cell counts
supported these data showing increased epithelial and stromal HGF labeling
after SP treatment with an increase in the percentage of HGF-positive fibroblasts
and macrophages. SP also increased expression of FGF-7/KGF in the infected
cornea in a similar pattern to HGF, increasing expression of the growth factor at
both the mRNA and protein level. FGF-7 is an epithelial cell-specific mitogen that
is secreted by stromal fibroblasts (Sotozono et al., 1994). Stimulation of human
keratinocytes with FGF-7 in vitro strongly enhances their proliferation and
differentiation (Marchese et al., 1990). Furthermore, topical application of FGF-7
to central corneal epithelial wounds accelerates healing with all wounds healed in
the FGF-7-treated group by 72 hours post-injury (Sotozono et al., 1995).
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However, in the SP-treated infected BALB/c cornea, despite elevated levels of
the growth factors, repair of corneal tissues does not occur. In order to explore
this further, we examined putative cell types and mechanisms that might
contribute to this outcome.
Both fibroblasts and macrophages are sources of growth factors in the cornea
and SP has been shown by others to increase their proliferation (Edwards et al.,
2009; Huo et al., 2009; Klenker et al., 2004; Guilbert et al., 1993). Using dualimmunostaining for either fibroblasts or macrophages, together with staining for
each of the growth factors, followed by cell counts, the percent of EGF positive
cells was no different for either cell type between SP vs. control groups. In
contrast, SP treatment significantly increased the percentage of HGF and FGF-7
positive cells, consistent with elevated levels of these growth factors at both the
mRNA and protein level. Moreover, we hypothesized that this increase in cell
number may be due to proliferation (Klenker et al., 2004; Imanishi et al., 2000) or
the persistence of these cells in the cornea, perhaps due to decreased apoptosis
(Jing et al., 2009; Zhou et al., 2008), as shown before for neutrophils. To test this
in vitro, elicited macrophages were stimulated with LPS with or without SP.
Following LPS and SP treatment, the anti-apoptotic gene Bcl-2 mRNA levels
were increased, while mRNA levels of the pro-apoptotic gene caspase-3 were
below the level of detectability. To confirm these in vitro data, we also tested
whole cornea for these genes and confirmed that mRNA levels of Bcl-2 were
increased and that caspase-3 was detectable and as anticipated, was
decreased. Past studies have demonstrated similar findings regarding apoptotic
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genes in trauma models of injury (burn) (Jing et al., 2009). In fact, blocking SP
binding to its major receptor, neurokinin-1, improved disease by increasing the
pro-apoptotic gene caspase-3, while the anti-apoptotic gene Bcl-2 was
decreased in the infected cornea of (susceptible) C57BL/6 mice who exhibit high
levels of SP in the cornea (Hazlett et al., 2007). Also, blocking SP interaction
with its receptor has been shown to induce apoptosis in a human laryngeal
carcinoma cell line (Muñoz et al., 2008). Taken together, these data support the
anti-apoptotic properties of SP that can contribute to stromal tissue damage,
which may provide a source of nutrients for bacterial growth, and worsened
disease outcome after P. aeruginosa infection (Zhou et al., 2010).
Another contributory effect leading to increased pathogenesis after SP
treatment was also explored in vitro in elicited LPS-stimulated macrophages.
Neurokinin-1 receptors for SP are present on these cells and during periods of
stress, SP binds to this receptor with high affinity (Li and Tseng, 1997) releasing
pro-inflammatory cytokines (i.e., IL-1β, IL-6, and TNF-α), as well as increasing
cellular phagocytic and chemotactic capacity (Muangman et al., 2009; Jing et al.,
2009). Thus, cytokine mRNA levels were measured in vitro after SP treatment
(with or without LPS) in BALB/c elicited macrophages. SP plus LPS increased
production of pro-inflammatory (e.g., IL-1β), while decreasing anti-inflammatory
cytokines (e.g., TGF-β). These data led us to hypothesize and test whether SP
upregulated M1 (NOS2-positive) and downregulated M2 (arginase-positive) types
of macrophages, contributing to worsened disease. However, immunostaining
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and cell counts provided evidence that only M2 type cells were reduced, with no
shift in the M1 population between treatment groups.
In summary, herein, we provide insight into the dual role of SP in this model
of bacterial infection. Evidence has been provided to show the effects of SP on
growth factors and stromal cells (e.g., macrophages and fibroblasts) in the
infected cornea. The neuropeptide upregulated growth factors (HGF and FGF-7),
but this was accompanied by upregulation of pro-inflammatory cytokines and
anti-apoptotic genes along with downregulation of anti-inflammatory cytokines
and pro-apoptotic genes. Furthermore, the neuropeptide decreased the number
of M2 types of macrophages, associated with tissue repair, with no effect on M1
type cells, associated with tissue destruction, all of which contribute to worsened
disease, despite elevated levels of the growth factors. Thus, the data
contraindicate the use of SP in an infected cornea, despite its clinical efficacy
and ability to promote corneal wound healing in the absence of infection
(Yamada et al., 2008).
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CHAPTER 3: mTOR regulates IL-10 and resistance to Pseudomonas
aeruginosa corneal infection.
ABSTRACT
IL-10 is important in the resistance response of BALB/c mice to experimental
Pseudomonas aeruginosa corneal infection. However, the cellular mechanism(s)
by which this anti-inflammatory cytokine is regulated remains unknown. Since the
mammalian target of rapamycin (mTOR), regulates IL-10 in other disease
models, the current study tested its role in bacterial keratitis. After infection,
corneas of rapamycin- vs. control-treated BALB/c mice showed worsened
disease and real-time RT-PCR confirmed that mTOR mRNA levels were
significantly decreased. Rapamycin treatment also increased clinical scores,
PMN infiltration (determined via MPO assay), and bacterial load, but PMN
bactericidal activity was diminished. Inhibition of mTOR also led to elevated
mRNA and protein levels of IL-12p40, matrix metalloproteinase 9 (MMP-9), and
iNOS, while mRNA and protein levels of IL-10, its regulator/effector STAT-3, and
SOCS3 (a pro-inflammatory cytokine regulator) were decreased. Furthermore,
mTOR inhibition delayed apoptosis, resulting in reduced levels of pro-apoptotic
caspase-3 and increased levels of Bcl-2 (anti-apoptotic). mTOR inhibition also
altered genes related to TLR signaling, including elevation of TLR4 and TLR5,
and IL-1R1, with decreases in IRAK-1 and an inhibitor of NFκB, NFκBIL-1.
Rapamycin treatment also increased levels of IFN-γ and Cebpb, a gene that
regulates expression of preprotachykinin-A (PPT-A; the precursor of Substance
P). Collectively, these data provide concrete evidence that mTOR regulates IL-10
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in P. aeruginosa-induced bacterial keratitis and is critical to balancing pro- and
anti-inflammatory events in cornea, resulting in better outcome to infection.
INTRODUCTION
Pseudomonas (P.) aeruginosa infection in resistant Th2-responder BALB/c
mice elicits production of both pro- and anti-inflammatory cytokines. Among
those that are anti-inflammatory, IL-10 has been show as critical in balancing
cytokines such as IFN-γ and decreasing stromal damage, while promoting
successful pathogen elimination (McClellan et al., 2008; McClellan et al., 2003).
Nevertheless, the cellular mechanisms regulating IL-10 in the P. aeruginosainfected cornea of BALB/c mice have not yet been determined. In this regard, in
other models, the mammalian target of rapamycin (mTOR) has been of interest
as it is upstream of IL-10 (Cheekatla et al., 2012; Baker et al., 2009; Weichhart et
al., 2008) and a target of a diverse array of microbes, growth factors, hormones,
and amino acids that elicit a host innate immune response.
mTOR itself is a serine-threonine kinase that also mediates cell growth and
proliferation, ribosome biogenesis, and cytoskeletal organization (Thomson et al.,
2009; Yang and Guan, 2007). It is contained within two functional complexes:
mTORC1 and mTORC2 and is active when complexed with Raptor, mLST8, and
PRAS40 (forming mTORC1), or when complexed with Rictor, mLST8, and Sin1
(forming mTORC2) (Thomson et al., 2009; Yang and Guan, 2007).
mTORC1 alone is sensitive to inhibition by the macrolide antibiotic rapamycin
that blocks the formation of the complex described above. Clinically, rapamycin is
used as an immunosuppressant in allogeneic transplantation. However, recent
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evidence has shown that if used in this manner, it has specific inflammatory side
effects, including: fever, anemia, and severe cases of glomerulonephritis
(Säemann et al., 2009). Moreover, inhibition of mTOR in mice can enhance LPSinduced shock that correlates with elevated levels of pro-inflammatory cytokines
such as IL-12p40 (Schmitz et al., 2008).
Similarly, another study showed that inhibition of mTOR in vivo diminished IL10 levels, while elevating IL-12p40, which was protective in experimental Listeria
monocytogenes infection (Weichhart et al., 2008). In contrast, it has been shown
that in corneal P. aeruginosa infection, IL-10 is required for resistance in the
BALB/c mouse and that if macrophages (a source of the cytokine) are depleted,
levels of IL-10 are decreased with concurrent elevation of IFN-γ, resulting in an
overall worsening of disease (McClellan et al., 2003).
PMN, one source of IL-12p40 (Hazlett et al., 2002) also are of prime
importance in bacterial keratitis. These cells are elevated in the cornea after
infection when BALB/c mice are treated with pro-inflammatory agents, such as
Substance P (SP) (McClellan et al., 2008). This suggests that bacterial clearance
should be enhanced in this model, but in fact, bacterial plate counts are
increased when compared with controls (McClellan et al., 2008). Thus the
bactericidal capacity of these cells to kill P. aeruginosa is not known and is
relevant to determine following rapamycin treatment, as its effects are similar to
treatment with SP (Foldenauer et al., 2012). Moreover, apoptosis is delayed in
SP-treated infected mice, which contributes to corneal perforation (Zhou et al.,
2008). In this regard, the effects of rapamycin also are unknown.
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In summary, this study provides evidence that IL-10 is regulated in the
infected cornea via the mTOR pathway. This conclusion is based upon data
showing that inhibition of mTOR by rapamycin decreased anti-inflammatory
cytokines, particularly IL-10, and upregulated several pro-inflammatory cytokines
(IL-12p40, IFN-γ) and their regulators. Furthermore, rapamycin downregulated
caspase-3 and upregulated Bcl-2, the latter prolonging inflammatory cell viability,
possibly further contributing to stromal destruction and unresolved disease.
MATERIALS AND METHODS
Mice. Female, 8-week-old, BALB/c mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and housed in accordance with the National
Institutes of Health guidelines. The animals were treated humanely in
accordance with the Association for Research in Vision and Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.
Bacterial culture and infection. P. aeruginosa cultures (strain 19660;
purchased from the American Type Culture Collection Manassas, VA) were
grown in peptone tryptic soy broth (PTSB) at 37°C on a 150 rpm rotary shaker for
18 h to an optical density reading between 1.3-1.8 at 540 nm. Stock cultures
were centrifuged at 6000 x g for 10 min, washed once with sterile saline, recentrifuged, and resuspended to a final concentration of approximately 1 x 106
CFU/µL (McClellan et al., 2003).

Under a stereoscopic microscope

(magnification=40X), a sterile 25 5/8 gauge needle was used to scar the left
central cornea of ethyl ether-anesthetized BALB/c mice. After which a 5 µL
suspension of P. aeruginosa was topically applied. To analyze phagocytic
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capacity, GFP-expressing P. aeruginosa was grown to a logarithmic phase in
PTSB with kanamycin (50 µg/mL), washed twice with PBS, resuspended and
diluted in PTSB (with kanamycin) and used as described below for phagocytosis
and bactericidal assays.
Ocular response to bacterial infection. Corneal disease was graded using an
established scale (Hazlett et al., 1987): 0 = clear or slight opacity, partially or fully
covering the pupil; +1 = slight opacity, fully covering the anterior segment; +2 =
dense opacity, partially or fully covering the pupil; +3 = dense opacity, covering
the entire anterior segment; and +4 = corneal perforation. After infection, a
clinical score was recorded (days 1, 3, and 5) for each group of mice
(n=5/group/treatment/assay). Lastly, representative corneas were photographed
with a slit lamp to document the effects of rapamycin inhibition of mTOR vs.
control treatment.
Rapamycin treatment. To test the appropriate vehicle and concentration of
rapamycin, BALB/c mice (n=5/group/time/assay) were anesthetized and
intraperitoneally injected with 100 µL of sodium carboxymethylcellulose
(Weichhart et al., 2008) (in Tween-80; Sigma-Aldrich, St. Louis, MO) or sterile
PBS (Mediatech, Manassas, VA) containing 1.5 or 3.0 mg/kg rapamycin (LC
Laboratories, Woburn, MA) on the day before infection (d= -1) and on days 1, 3,
and 5 post-infection (p.i.). Use of either sodium carboxymethylcellulose or sterile
PBS yielded similar results (data not shown), thus, subsequent experiments used
PBS as the vehicle (control) for rapamycin. Furthermore, these experiments
tested the optimal concentration for rapamycin in this model system (doses

55
above). Results indicated that 3.0 vs.1.5 mg/kg rapamycin vs. PBS control
treatment significantly lowered IL-10 protein levels (comparative data not shown)
and thus all subsequent experiments were done using the higher concentration.
Quantification of corneal PMN. An MPO (myeloperoxidase) assay was used to
quantitate the polymorphonuclear neutrophilic (PMN) leukocyte infiltrate in the
corneas of rapamycin- and PBS-treated BALB/c mice (n=5/group/time) at 1 and 3
days p.i. Corneas were harvested, homogenized in 1 mL of potassium phosphate
buffer (50 mM, pH 6.0) containing 0.5% hexodecyltrimethylammonium bromide
(Sigma-Aldrich) using glass micro-tissue grinders. The samples were freezethawed four times and centrifuged at 14,000 rpm for 10 min. To measure MPO, a
100 µL sample of supernatant was added to fresh 2.9 mL o-dianisidine
dihydrochloride substrate buffer (16.7 mg/mL; Sigma-Aldrich) with 0.0005%
hydrogen peroxide. The change in absorbance at 460 nm was read every 30
seconds for 5 min on a Heλios α spectrophotometer (Thermo Fisher Scientific,
Waltham, MA). Afterward, the units of MPO/cornea were calculated: one unit of
MPO activity is equivalent to approximately 2 x 105 PMN/µL (Williams et al.,
1983).
Quantification of viable bacteria. Bacteria were quantitated at 1 and 3 days p.i.
in individual infected corneas of BALB/c mice (n=5/group/time) after rapamycin or
PBS treatment. Each cornea was homogenized in 1 mL sterile PBS containing
0.25% BSA; 100 µL of the corneal homogenate was serially diluted 1:10 in the
same solution. Select dilutions were plated in triplicate on pseudomonas isolation
agar plates (Becton-Dickinson Company, Sparks, MD). Plates were incubated
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overnight at 37ºC and the number of viable bacteria manually counted. Results
are reported as 103 CFU/cornea + SEM.
Quantification of corneal PMN phagocytic and intercellular killing capacity.
PMN from BALB/c mice were isolated (Luo, 1997) and processed essentially as
described before (Szliter et al., 2007). Briefly, mice received an i.p. injection of a
9% casein solution (1.0 mL) and a second identical injection 24 h later. PMN
were lavaged from the peritoneal cavity 3 h after the second injection, washed,
and isolated using a Percoll gradient. Viable cells (>95%) were stained with
Trypan blue and counted using a Cellometer Vision CBA Analysis System v.
2.1.0. (Nexcelon Bioscience LLC, Lawrence, MA) and resuspended in RPMI
(with 10% FBS) at the desired concentration for in vitro stimulation. Cells were
treated with rapamycin (0.01 µM and 1.0 µM) or sterile 1X PBS (negative and
positive controls) for 18 h at 37ºC. Cells were washed to remove the inhibitor and
then resuspended in media.
For phagocytosis and killing assays (Hazlett et al., 1999), 1 x 106 CFU/µL of
GFP-labeled bacteria was added to each well (a ratio of 2.5:1, bacteria to PMN)
of a twelve-well plate, omitting addition to the negative control wells. Plates were
centrifuged at 500 x g for 10 min and then incubated for 2 h at 37ºC. Cells were
washed twice to remove bacteria, then incubated with 0.04% Trypan blue to
quench the fluorescence of surface-associated bacteria and to again test PMN
viability (>87.4%).
To analyze intracellular killing, PMN were incubated with P. aeruginosa,
harvested, and treated as above. Then, after 1 h incubation at 37ºC, 200 µg/mL
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gentamicin was added for an additional 3 h to ensure killing of extracellular
bacteria (Hazlett et al., 1999). Cells were washed twice with 2X Hank’s Balanced
Salt Solution (HBSS). Supernatant was removed and 0.5 mL of ice-cold water
was added to lyse PMN. Samples were kept on ice for 10 min after which 0.5 mL
2X HBSS was added to a final volume of 1 mL. 250 µL of cell suspension was
plated in triplicate on pseudomonas isolation agar (Becton-Dickinson) and
incubated for 24 h at 37ºC. Afterward, colonies were manually counted and
recorded as the mean CFU + SEM.
Real-time RT-PCR. Mice were sacrificed; normal and infected corneas from
rapamycin- and PBS-treated mice (n=5/group/time) were removed (1, 3, and 5
days p.i.). Individual corneas were briefly stored in RNA STAT-60™ (Tel-Test,
Friendswood, TX) at -20ºC before processing. Total corneal RNA was extracted
with chloroform (200 µL/mL RNA STAT-60™; Sigma-Aldrich) and precipitated
overnight with isopropanol (500 µL/mL RNA STAT-60™; Sigma-Aldrich).
Samples were washed in cold 75% ethanol. To produce a cDNA template for the
PCR reaction, 1 µg of each RNA sample was reverse transcribed using Moloneymurine leukemia virus (M-MLV). The 20 µL mixture contained 200U M-MLVreverse transcriptase, 10U of RNase inhibitor, 500 ng oligo(dT) primers, 10mM
dNTPs, 100mM DTT, and M-MLV reaction buffer (all from Invitrogen, Carlsbad,
CA). cDNA products were diluted 1:25 with diethylpyrocarbonate-treated water
and a 2 µL cDNA aliquot was used for real-time RT-PCR. mRNA levels of mTOR,
STAT-3, IL-10, IL-12p40, inducible nitric oxide synthase (iNOS), matrix
metalloproteinase-9 (MMP-9), suppressor of cytokine signaling 3 (SOCS3),
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caspase-3, B cell lymphoma (Bcl)-2, Cebpb, NFκB inhibitor-like 1 (NFκBIL-1),
TLR4, TLR5, IFN-γ, IL-1 receptor (IL-1R1), and interleukin-1 receptor-associated
kinase 1 (IRAK-1) were tested by real-time RT-PCR (MyiQTM Single Color RealTime PCR Detection System; Bio-Rad, Hercules, CA). Real-Time SYBR®
Green/Fluorescein PCR Master Mix (Bio-Rad) was used for the PCR reaction
with primer concentrations of 10 µM. After a pre-programmed hot start cycle (3
min at 95ºC), the parameters used for PCR amplification were: 15 sec at 95ºC
and 60 sec at 60ºC with the cycles repeated 45 times. The fold differences in
gene expression were calculated after normalization to β-actin and are
expressed as the relative mRNA concentration + SEM. The primer pair
sequences used for real-time RT-PCR are shown in Table 1.
ELISA. After mice were treated with rapamycin or sterile PBS, IL-10, IL-12p40, pSTAT-3, Cebpb, and IFN-γ protein levels were determined in normal and infected
corneas (n=5/group/time) using ELISA kits (R&D Systems, Minneapolis, MN;
except Cebpb which was purchased through antibodies-online.com, Atlanta, GA).
For these assays, tissue was prepared as described before (McClellan et al.,
2008). 50 µL (IL-12p40, IFN-γ) or 100 µL (IL-10, p-STAT-3, and Cebpb) aliquots
of each supernatant were assayed in duplicate according to the manufacturer’s
instructions (R&D Systems; Cebpb – antibodies-online.com). Sensitivities for the
assays were: >4.0 pg/mL (IL-10), 0.6 - 2.7 pg/mL (IL-12p40), 33 pg/mL (Cebpb),
>2.0 pg/mL (IFN-γ), and >4.48 pg/mL (p-STAT-3) (R&D Systems). Results are
expressed as pg/mL (fg/mL only for IFN-γ) of protein + SEM.
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Gene

GenBank No.

β-Actin

NM_007393.3

Bcl-2

NM_009741
NM_177410.2

caspase-3

NM_009810.2

Cebpb

NM_009883.3

IFN-γ

NM_008337.3

IL-1R1

NM_001123382.1
NM_008362.2

IL-10

NM_010548.2

IL-12p40

NM_008352.2

iNOS

NM_010927.3

IRAK-1

NM_008363.2

MMP-9

NM_013599.2

mTOR

NM_020009.2

NFκBIL-1

NM_010909.4

SOCS3

NM_007707.3

STAT-3

NM_011486.4

TLR4

NM_021297.2

TLR5

NM_016928.2

Primer Sequence (5’ - 3’)
F - GAT TAC TGC TCT GGC TCC TAG C
R - GAC TCA TCG TAC TCC TGC TTG C
F - GGA CTT GAA GTG CCA TTG GT
R - AGC CCC TCT GTG ACA GCT TA
F - TGG GCC TGA AAT ACC AAG TC
R - AAA TGA CCC CTT CAT CAC CA
F - TGATGCAATCCGGATCAA
R - CACGTGTGTTGCGTCAGTC
F - GTT ACT GCC ACG GCA CAG TCA TTG
R - ACC ATC CTT TTG CCA GTT CCT CCA G
F - CTC TGC TTC TTG ACA ACG TGA GCT TC
R - TAT AGT CCC CTC TGT GCT CTT CAG CC
F - TGC TAA CCG ACT CCT TAA TGC AGG AC
R - CCT TGA TTT CTG GGC CAT GCT TCT C
F - GGT CAC ACT GGA CCA AAG GGA CTA TG
R - ATT CTG CTG CCG TGC TTC CAA C
F - TCC TCA CTG GGA CAG CAC AGA ATG
R - GTG TCA TGC AAA ATC TCT CCA CTG CC
F - CAGAACCACCACAGATCATCATC
R - GGCTATCCAAGACCCCTTCTTC
F - CTC TAC AGA GTC TTT GAG TCC GGC AG
R - TCA GGA ACT TCC AGT ACC AAC CGT C
F - ACC GGC ACA CAT TTG AAG AAG
R - CTC GTT GAG GAT CAG CAA GG
F - CCCTGATGCTTACACGGACTT
R - CAGCCCAGAATCTGCCCAG
F - GGG GAC CAA GAA CCT ACG C
R - CTG GAG GCG GCA TGT AGT G
F - TGG CAC CTT GGA TTG AGA GTC
R - GCA GGA ATC GGC TAT ATT GCT
F - CGC TTT CAC CTC TGC CTT CAC TAC AG
R - ACA CTA CCA CAA TAA CCT TCC GGC TC
F - TGC TCA AAC ACC TGG ATG CTC ACT AC
R - ACA GCC GCC TGG ATG TTG GAG ATA TG

Table 1. Nucleotide sequences of mouse primers for real-time RT-PCR.

Size
(bp)
147
127
147
63
125
87
126
121
118
87
119
110
105
131
117
109
112

60
Immunohistochemistry. After sacrificing mice, normal and 1 and 5 days p.i.
eyes were enucleated from rapamycin- or PBS-treated animals (n=5/group/time),
embedded in optimal cutting temperature (OCT) compound (Sakura Finetek
USA, Torrance, CA) and snap frozen in liquid nitrogen. Sections (10 µm) were
cut, fixed in acetone, and incubated in blocking agent as described before
(McClellan et al., 2003). Sections were simultaneously incubated with individual
primary antibodies: rabbit anti-mouse caspase-3 (1:800; Cell Signaling, Danvers,
MA) and hamster anti-mouse Bcl-2 (1:100; BD Biosciences, San Jose, CA) in
blocking agent for 1 h. Then, sections were rinsed with phosphate buffer and
incubated for another hour with Alexa Fluor 633 goat anti-rabbit secondary
antibody for caspase-3 (1:1500; Invitrogen) and Alexa Fluor 546 goat antihamster for Bcl-2 (1:1500; Molecular Probes, Eugene, OR) in 0.01M Tris-HCl
buffer. Sections were rinsed in the latter buffer and then incubated with nuclear
acid stain (SYTOX® Green, 1:20,000; Lonza, Walkersville, MD) and rinsed
again. Digital images were captured on a confocal laser-scanning microscope
(TCS SP2, Leica Microsystems Inc., Buffalo Grove, IL). Negative controls for
each group were processed similarly, with the exception that each primary
antibody was replaced by the same host species IgG.
Nitrite concentration (Griess assay). NO production was measured in
uninfected corneas and 1 and 5 day p.i. after PBS vs. rapamycintreatment
(n=5/group/time) using Griess reagent (Sigma-Aldrich) which quantifies the
stable end product nitrite. Corneal samples were homogenized in sterile PBS
with micro-tissue grinders and 100 µL aliquots were incubated in 100 µL Griess
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reagent for 15 min at room temperature. Absorbance was measured at 570 nm
and nitrite concentrations calculated using a sodium nitrite standard curve. The
data is reported as the mean µM/cornea concentration of nitrite + SEM.
Toll-like receptor PCR array. The corneas of rapamycin- vs. PBS-treated mice
(n=5/group/time) were harvested at three days p.i., pooled, and processed for
cDNA using a RT2 First Strand Kit (Qiagen Inc., Valencia, CA). mRNA levels of
84 genes were profiled using a Toll-Like Receptor RT2 ProfilerTM PCR Array
(Qiagen Inc.). Selected genes that had at least a two-fold or greater change were
tested by real-time RT-PCR and ELISA assay.
Statistical analysis. The difference in clinical score between two groups was
tested by the Mann-Whitney U test. For all other experiments, an unpaired, twotailed, Student’s t test (for comparisons between two groups) was used. All data
were considered significant at p < 0.05. Each experiment was repeated at least
once to ensure reproducibility and data from a representative experiment are
shown. Quantitative data is expressed as the mean + the standard error of the
mean (SEM).
RESULTS
Disease response, mTOR inhibition, and PMN infiltration.

More severe

disease (Fig. 16A) was seen after rapamycin treatment at 3 and 5 days p.i.
(p=0.02 for both) when compared with PBS-treated controls; no significant
difference was observed at 1 day p.i. Photographs taken with slit lamp of
representative eyes from both groups at 5 days p.i. (Fig. 16B, C) confirmed that
rapamycin treatment increased corneal opacity and resulted in corneal thinning
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(Fig. 16B), while the cornea of PBS-treated mice exhibited slight central opacity
(Fig. 16C). mTOR mRNA levels also were tested using real-time RT-PCR (Fig.
16D). Rapamycin significantly downregulated mTOR when compared to PBS
controls at all time points tested, but only significantly in the normal, uninfected
cornea and at 1 and 5 days p.i. (p=0.0004, p=0.05, p=0.04). An MPO assay was
used to quantitate PMN in the infected cornea of both groups (Fig. 16E) and
revealed that after rapamycin vs. PBS treatment, MPO levels were significantly
increased at 3 (p=0.007), but did not differ between groups at 1 day p.i.

Figure 16. Effects of rapamycin treatment in vivo. Clinical scores (A) were significantly increased
at 3 and 5 days p.i. in rapamycin- vs. PBS-treated mice. Photographs with a slit lamp confirmed
that the cornea of rapamycin- (B) vs. PBS- (C) treated mice had increased opacity and corneal
thinning. Rapamycin vs. PBS also significantly decreased mTOR mRNA levels (D) in normal
uninfected cornea, and at 1 and 5 days p.i. MPO levels (E) were significantly elevated at 3 days
p.i. in rapamycin- vs. PBS-treated mice, with no differences at 1 day p.i. Magnification=7X.
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Bacterial load, PMN phagocytosis, and intracellular killing. Viable bacterial
load in the cornea of rapamycin- vs. PBS-treated mice was significantly higher at
3 days p.i. (Fig. 17A; p<0.0001); no significant difference was observed at 1 day
p.i. A phagocytosis assay comparing PBS with no bacteria (negative control),
plus bacteria (positive control), and rapamycin at either 0.01 or 1.0 µM showed
no differences in phagocytic capability between groups and no growth in the
negative control, as expected (Fig. 17B). Figure 17C illustrates the similarity in
appearance of phagocytized GFP-positive cells amongst all groups, except the
negative control. The ability of PMN to kill bacteria was similarly assessed and
was significantly compromised (Fig. 17D; p=0.04) at a concentration of 1.0 µM
rapamycin only.

Figure 17. Rapamycin effects on phagocytosis and PMN intracellular killing. (A) Bacterial load
was significantly elevated at 3 days p.i. in rapamycin- vs. PBS-treated mice, with no differences at
1 day p.i. (B) Rapamycin treatment (0.01 µM or 1.0 µM) had no significant effect on phagocytosis
when comparing the number of PMN containing GFP+ bacteria with the positive control; (C)
illustrates the graphic data. Magnification = 40X. (D) Plate counts assessed bacterial killing and
only 1.0 µM rapamycin showed a significant increase in bacterial load over all other groups.
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Real-time RT-PCR of STAT-3, IL-10, and IL-12p40. The balance between proand anti-inflammatory cytokines is critical to disease resistance in the infected
cornea of BALB/c mice (McClellan et al., 2008; McClellan et al., 2003). Thus,
real-time RT-PCR was used to characterize the role of mTOR in their regulation
(Fig. 18 A-F). Figure 18 (A, C, E) shows corneal mRNA levels of STAT-3, IL-10,
and IL-12p40 after rapamycin or PBS treatment. Rapamycin treatment resulted in
a significant increase in STAT-3 mRNA expression (Fig. 18A) in the normal

Figure 18. Effects of rapamycin treatment on STAT-3, IL-10, and IL-12p40 expression levels in
cornea. After rapamycin treatment: STAT-3 mRNA (A) levels were downregulated at 3 and 5
days p.i., but increased in the normal uninfected cornea and unchanged at 1 day p.i.; mRNA
levels of IL-10 (C) were decreased at 1 and 5 days p.i., undetected in the normal uninfected eye
and no different between groups at 3 days p.i.; IL-12p40 (E) mRNA levels were increased at 1
and 3 days p.i., but did not differ between groups at 5 days p.i. or in the normal cornea. For
protein, p-STAT-3 (B) was downregulated after rapamycin treatment in normal and at 1 and 3
days p.i. IL-10 protein levels (D) were not detected in either group in normal cornea, but
decreased after rapamycin treatment at 5 days p.i. IL-12p40 protein (F) was increased at 3 days
p.i., but did not differ between groups in the normal cornea or at 1 day p.i.

65
cornea and a decrease at 3 and 5 days after infection (p<0.0001, p<0.0001,
p=0.05) when compared to PBS controls. No difference was detected at 1 day
p.i. between the two groups. IL-10 mRNA expression (Fig. 18C) was significantly
decreased at 1 and 5 days after infection (p=0.03 and p=0.04) following
rapamycin treatment, with no difference between groups in the normal cornea or
at 3 days p.i. In contrast, IL-12p40 mRNA (Fig. 18E) was significantly increased
in the rapamycin-treated group at 1 and 3 days p.i. (p=0.009 and p<0.0001) with
no difference between groups in the normal cornea or at 5 days p.i.
ELISA analysis. To selectively confirm the real-time RT-PCR data, ELISA
assays were performed to determine the protein levels of p-STAT-3, IL-10, and
IL-12p40 (Fig. 18B, D, F). Rapamycin treatment significantly decreased levels of
p-STAT-3 (Fig. 18B), the activated form of STAT-3, in the normal cornea and at 1
and 5 days p.i. (p=0.006, p=0.03, p=0.02). In the normal cornea, IL-10 protein
levels were below detectability for both groups (Fig. 18D). However, at 5 days
p.i., rapamycin treatment significantly decreased IL-10 levels compared to control
(p=0.03). In contrast, IL-12p40 (Fig. 18F) was significantly increased in the
rapamycin-treated group at 3 days p.i. (p=0.03) with no differences seen between
groups in the normal cornea or 1 day after infection.
Real-time RT-PCR of IL-10 effectors. To explore the impact of IL-10
downregulation, real-time RT-PCR was used to test several downstream
effectors of IL-10: SOCS3, MMP-9, and iNOS (Fig. 19A-C). Treatment with
rapamycin significantly decreased mRNA levels of the pro-inflammatory cytokine
regulator SOCS3 (Fig. 19A) at both 1 and 5 days p.i. (p<0.0001 and p=0.03)
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compared to PBS controls, with no difference between groups in the normal
cornea. In contrast, rapamycin treatment significantly increased levels of MMP-9
at 5 days p.i. (Fig. 19B; p=0.05) with no differences between groups in the
normal cornea or at 1 day p.i. Furthermore, the nitric oxide (NO) catalyzing
enzyme iNOS was significantly upregulated after rapamycin vs. PBS treatment
(Fig. 19C) in the normal cornea and at both 1 and 5 days after infection (p=0.01,
p=0.02, p=0.02).

Figure 19. Response of IL-10 effectors to rapamycin treatment. mRNA levels for SOCS3 (A)
were significantly decreased at 1 and 5 days p.i. after rapamycin vs. PBS treatment. mRNA levels
of MMP-9 (B) were upregulated at 5 days p.i., while iNOS mRNA levels (C) were significantly
increased in normal cornea and at 1 and 5 days p.i. Nitrite levels (D) were significantly increased
in the rapamycin-treated group only at 5 days p.i.

Griess analysis of nitrite production. Levels of NO were tested using a Griess
assay that measures nitrite concentration (Fig. 19D). At 1 day p.i., there was no
significant difference in corneal nitrite levels between PBS- and rapamycin-
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treated mice. However, by 5 days p.i., nitrite levels were significantly increased in
the rapamycin-treated group (p=0.02).

2

Figure 20. TLR RT Profiler PCR array and real-time RT-PCR comparing rapamycin to PBS
treatment. A scatter plot of several genes from PCR array that exhibited at least 2-fold change at
3 days p.i. are shown (A). These also were tested by RT-PCR: mRNA levels for TLR4 (B) were
elevated in the normal uninfected cornea and at 1 and 5 days p.i; TLR5 mRNA levels (C) were
upregulated in normal and at 1 day, but not 5 days p.i. IRAK-1 levels (D) were elevated in normal,
unchanged at 1 and decreased at 5 days p.i. For IL-1R1 (E), levels were increased in the normal
and at 1 day p.i., but were not significantly different at 5 days p.i. For NFκBIL-1 (F), levels were
increased in normal, but decreased at 1 and 5 days p.i.

RT-PCR array and real-time RT-PCR of TLR-related genes. TLR-related
genes were profiled in the cornea at 3 days p.i. using a RT-PCR array. Several
genes with greater than 2-fold changes in expression were selected for further
analysis using real-time RT-PCR (labeled in Fig. 20A and shown in Table 2):
TLR4, TLR5, IRAK-1, NFκBIL-1, IL-1R1, IFN-γ, and Cebpb.
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GENE

FOLD UP- OR DOWNREGULATION

Cebpb
IFN-γ
IL-1R1
IRAK-1
NFκBIL-1
TLR4
TLR5

3.09
3.00
4.07
3.31
-2.57
3.12
2.63
2

Table 2. Selected TLRs from the Toll-Like Receptor RT Profiler PCR array

Rapamycin treatment significantly increased expression of TLR4 in the
normal cornea and at 1 and 5 day p.i. (Fig. 20B; p=0.002, p=0.02, p=0.02). TLR5
mRNA levels also were increased in the normal cornea and at 1 day p.i. (Fig.
20C; p=0.004, p=0.003) with no significant change at 5 days p.i. IRAK-1, whose
signaling leads to the translocation of NFκB from the cytoplasm to the nucleus,
was significantly upregulated with rapamycin treatment in the normal cornea (Fig.
20D, p=0.009) but by 5 days p.i., levels were downregulated (Fig. 20D; p=0.002).
IL-1R1 was significantly increased by rapamycin treatment in the normal cornea
and at 1 day p.i. (Fig. 20E; p<0.0001 and p=0.009). No significant difference was
observed at 5 days p.i. Finally, an inhibitor of NFκB translocation to the nucleus,
NFκBIL-1, was significantly downregulated with rapamycin treatment at 1 and 5
days p.i. but upregulated in the normal cornea (Fig. 20F; p=0.04, p<0.0001,
p=0.03).
Cebpb and IFN-γ. Rapamycin treatment significantly increased mRNA levels of
pro-inflammatory Cebpb in the normal cornea and at 1 and 5 days after infection
(Fig. 21A; p<0.0001, p=0.001, p=0.002). Likewise, IFN-γ was upregulated in the
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rapamycin-treated group in the normal cornea and at 1 and 5 days p.i. (Fig. 21C;
p=0.02, p=0.04, p=0.004). Rapamycin inhibition of mTOR also resulted in an
increase in protein levels of Cebpb at 1 and 5 days p.i. (Fig. 21B, p=0.02,
p<0.0001). It also resulted in increased IFN-γ expression at 6 days p.i., with no
difference between groups at 1 day p.i. (Fig. 21D).

Figure 21. Effect of rapamycin vs. PBS treatment on pro-inflammatory cytokines. Rapamycin
treatment significantly increased Cebpb mRNA (A) and IFN-γ (C) in the normal cornea and at 1
and 5 days p.i. Cebpb protein levels (B) were increased at 1 and 5 days p.i., but did not differ
between groups in the normal cornea. IFN-γ protein (D) was significantly increased at 6 days p.i.,
but was undetectable at 1 day p.i. in either group.

Apoptosis: RT-PCR and immunohistochemistry. To test the effects of
rapamycin treatment on apoptosis, caspase-3 and Bcl-2 were assayed by realtime RT-PCR and immunostaining. Caspase-3 (Fig. 22A) was significantly
decreased in the normal cornea of rapamycin- vs. PBS-treated group and at 1
day p.i. (p=0.04 for both). However, no significant changes between groups were
seen at day 3 p.i. Bcl-2 was significantly increased in the normal cornea and at 1
and 3 days p.i. (Fig. 22B; p=0.0001, p=0.003, and p<0.0001).
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Qualitative differences in immunostaining for caspase-3 (blue) and Bcl-2 (red)
were detected between rapamycin- vs. PBS-treated groups (Fig. 22C) at 1 and 5
days p.i. Bcl-2 staining was markedly more intense at 1 and 5 days p.i. in the
rapamycin-treated group while caspase-3 was barely detectable when compared
with PBS controls. In the PBS group, staining for caspase-3 was increased at 1
and 5 days p.i., while Bcl-2 staining was barely detectable. Representative same
host species IgG negative controls are shown for the rapamycin- and PBStreated groups.

Figure 22. Effect of rapamycin treatment on apoptosis. Rapamycin vs. PBS treatment: (A)
significantly downregulated caspase-3 mRNA in the normal cornea and at 1 day p.i. with no
differences between groups at 3 days p.i.; (B) Bcl-2 mRNA was upregulated in normal cornea
and at 1 and 3 days p.i. (C) Merged confocal images show a decrease in caspase-3 (blue) and
increase in Bcl-2 (red) at 1 and 5 days p.i. in the cornea of rapamycin- vs. PBS-treated mice.
Controls in which the primary antibody was replaced with same host species IgG were negative.
SYTOX® Green (green) was used for nuclear labeling. Magnification=208X.
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DISCUSSION
Previously, this laboratory has demonstrated that administration of rIL-10 to
susceptible Th1-responder C57BL/6 mice provides protection against P.
aeruginosa infection by limiting the pro-inflammatory cytokine response mediated
by IL-12p40, including IFN-γ production (McClellan et al., 2003). In contrast, IL10 downregulates IFN-γ and contributes to the resistance of Th2-responder
BALB/c mice (McClellan et al., 2003). The present work expands upon these
findings by examining the relationship between IL-10 and its regulation by mTOR
in the infected BALB/c cornea.
mTOR is an upstream regulator of immunoregulatory cytokines (e.g., IL-10) in
other disease paradigms and is implicated in both growth and inflammatory
pathways (Baker et al., 2009; Weichhart et al., 2008). Previous work also has
shown that mTOR plays a role in regulating the IL-10/IL-12p40 axis in LPSstimulated macrophages and controls the innate immune response (Cheekatla et
al., 2012).
The present work has specifically demonstrated the adverse effects of
rapamycin treatment after P. aeruginosa infection in the cornea. The data provide
evidence that decreased IL-10 and increased IL-12p40 levels are the foundation
for these effects. Pro-inflammatory cytokines such as IL-12p40 are essential to
amplify the innate immune response, with anti-inflammatory cytokines such as IL10 counterbalancing these effects, keeping the inflammatory response in check
(Cheekatla et al., 2012).
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Inhibition of mTOR gene activation is a common technique used to
characterize mTOR’s function and rapamycin is an often-used inhibitor that acts
at this level (Cheekatla et al., 2012; Baker et al., 2009; Thomson et al., 2009;
Weichhart et al., 2008; Yang and Guan, 2007). Despite assertions that the action
of rapamycin might be advantageous clinically to treat inflammatory conditions
and as a prophylactic for graft rejection, studies have demonstrated deleterious
side effects that are supported by the studies reported herein. In this regard,
Säemann, et al. (2009) reviewed the role of mTOR inhibition by rapamycin in
transplant immunity and found that, despite preliminary benefits to prevent
rejection, a host of hyperinflammatory side effects accompanied its use,
including: rash, fever, pneumonitis, glomerulonephritis, and anemia. Another
study showed that administration of rapamycin increased the lethality of
endotoxin (LPS)-mediated shock in mice (Schmitz et al., 2008).

Moreover,

concern is mounting against the use of rapamycin because adverse side effects
have included resistance to antimicrobial therapy (Weiner et al., 2007).
These side effects suggest that inhibition of mTOR has profound impact on
elements of the inflammatory response, including infiltrating cells such as PMN.
Herein we have shown that rapamycin increased PMN number in the infected
cornea; this implies that bacterial clearance should be enhanced, however, viable
bacterial plate counts were increased when compared with controls. Thus the
bactericidal capacity of these cells to kill Pseudomonas was examined and, while
the ability of the PMN to phagocytize bacteria was not changed, rapamycin
treatment decreased intracellular killing capacity. Likewise, another study of the
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effects of rapamycin on PMN function (in cirrhosis patients) revealed that
inhibition of mTOR impaired PMN bactericidal activity but not uptake, supporting
the current studies reported herein (Rolas et al., 2012).
Furthermore, our data show that rapamycin upregulated deleterious
downstream effectors of IL-10 (e.g., MMP-9, iNOS), and downregulated
cytokines that participate in control of the inflammatory response (e.g., SOCS3,
STAT-3). The data are in good agreement with past studies in that others have
shown that SOCS3 is a mediator of LPS-stimulated IL-10 release in response to
infection (Berlato et al., 2002). In addition, SOCS3-deficient mice are vulnerable
to enhanced expression of Th1 inflammatory cytokines promoting infiltration of
inflammatory cells (e.g., PMN, macrophage, T-cells) (Qin et al., 2012).
STAT-3, when activated, has been shown to decrease levels of TNF-α and
IL-12p40 and can lead to a state of hyperinflammation (Qin et al., 2012). Here we
have demonstrated that treatment with rapamycin significantly decreased the
expression of activated p-STAT-3, consistent with the above report.
Previously, our laboratory demonstrated that rMMP-9-treated BALB/c mice
exhibited worsened disease based on increased clinical score, MPO,
Langerhans cell number, and protein levels of pro-inflammatory cytokines
(McClellan et al., 2006). MMP-9 is among the most widely studied MMP in the
cornea as it preferentially degrades basement-membrane components such as
type IV collagen. Here, loss of mTOR signaling led to an increase in MMP-9
mRNA. Furthermore, PMN are a source of matrix metalloproteinases (McClellan
et al., 2006) and since rapamycin increased the number of these cells in the
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cornea after infection, it is likely that they contribute to elevated levels of MMP-9.
Ultimately, this increase contributes to destruction of the corneal stromal
cytoarchitecture and decreased ability for tissue restoration (McClellan et al.,
2006).
Berlato, et al. (2002) observed a correlation between decreased inducible NO
synthase (iNOS) levels and cells that were treated with IL-10. This is consistent
with our data as we have shown that inhibition of mTOR elevates iNOS and
nitrite levels. In previous reports, our laboratory has shown that iNOS is
constitutively expressed in the BALB/c cornea and is required for bacterial killing
(Hazlett et al., 2005). However, overproduction of iNOS-derived NO (through
upregulation of IFN-γ) is associated with susceptibility to P. aeruginosa infection
(McClellan et al., 2006) and these past data are consistent with current studies.
Herein, we establish that rapamycin affects numerous elements of the TLR
pathway that are instrumental in the response to P. aeruginosa infection. Others
have characterized TLR4 and TLR5 as regulators of P. aeruginosa-induced
keratitis in macrophages (Sun et al., 2010). In our laboratory, we have
demonstrated that TLR4 is constitutively produced and activated in the BALB/c
cornea after infection (Huang et al., 2006). Its signaling cascade includes IRAK-1
and leads to the translocation of NFκB from the cellular cytoplasm to the nucleus,
causing the transcription of pro-inflammatory genes such as IFN-γ and IL-1β
(whose receptor, IL-1R1, is also upregulated by rapamycin). Presently, we have
shown that rapamycin-treated mice have increased levels of TLR4, TLR5, and
IRAK-1 mRNA, indicating increased stimulation of the pro-inflammatory pathway.
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Moreover, we also demonstrated that an inhibitor of NFκB translocation, NFκBIL1, is downregulated in response to rapamycin treatment.
Cebpb increases expression of the PPT-A gene that gives rise to Substance
P (SP) (Kovács et al., 2006), a pro-inflammatory neuropeptide that worsens
bacterial keratitis in BALB/c mice (McClellan et al., 2008). In fact, we have shown
that rapamycin and SP elicit a similar pattern of response in the P. aeruginosainfected BALB/c cornea, with a similar outcome (Foldenauer et al., 2012). Here
we have demonstrated that Cebpb is significantly upregulated in rapamycintreated mice (mRNA, protein), however, SP regulation by Cebpb in the cornea
has been untested and may require further examination.
Lastly, tight regulation of the balance between apoptosis and cell survival, as
well as, the timing of apoptotic events, is critical to immune defense (Zhou et al.,
2008; Ren and Savill, 1998). Others have shown that persistence of apoptotic
cells can worsen disease outcome (Zhou et al., 2008; Ren and Savill, 1998). In
the susceptible C57BL/6 mouse, we have shown that PMN have delayed
apoptosis that contributes to inflammation-induced tissue damage (Zhou et al.,
2008). In the same study, administration of SP to resistant BALB/c mice delayed
apoptosis, leading to a similar outcome of worsened disease. Another study
reported that in a mouse model of LPS-induced acute lung injury, delay of
apoptosis prolonged the inflammatory response (Rowe et al., 2002). Our work
also revealed that rapamycin treatment delayed apoptosis, which again is
consistent with past studies and with the poor outcome of enhanced disease
after infection.
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In summary, inhibition of mTOR by rapamycin increased disease in the
cornea of resistant BALB/c mice through downregulation of the anti-inflammatory
cytokine IL-10, and upregulation of pro-inflammatory IL-12p40. Furthermore, the
absence of IL-10 led to dysregulation of several downstream effectors: MMP-9,
SOCS3, STAT-3, and iNOS and elements of the TLR pathway: TLR4, TLR5,
IRAK-1, IL-1R1, NFκBIL-1, Cebpb, and IFN-γ. Moreover, we have demonstrated
that loss of mTOR signaling generates an anti-apoptotic corneal environment in
which damaged and dying cells could contribute to further tissue destruction.
Lastly, rapamycin treatment increased PMN number, but reduced their capacity
for intracellular killing. Taken together, these data support the tenant that loss of
mTOR signaling elicits a dysregulated pro-inflammatory response in the infected
BALB/c cornea that exacerbates Pseudomonas aeruginosa keratitis.
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CHAPTER 4: The role of VIP in the cornea
ABSTRACT
Purpose: Exogenous vasoactive intestinal peptide (VIP) downregulates pro- but
upregulates anti-inflammatory cytokines, growth factors (GFs) and Toll like
receptors (TLR) promoting healing in experimental P. aeruginosa keratitis.
Whether VIP is required for GF or GF receptor (R) expression in normal and
infected cornea is unknown and the purpose of this study. Methods: VIP
knockout (-/-) and wild type (WT) C57BL/6 (B6) mice were infected and tested
using PCR array, real-time RT-PCR, ELISA, and immunostaining. VIP antagonist
treatment studies also were done using B6 and BALB/c mice. Results: Infected
corneas of VIP-/- vs. WT B6 mice perforated earlier [2 vs. 5 days postinfection
(p.i.)] and array data showed that GFs were differentially changed between
groups. RT-PCR revealed that the infected cornea of VIP-/- vs. WT mice
expressed higher mRNA levels of EGF and HGF, reduced FGF, EGFR and
HGFR, with no difference in FGFR; differences between groups were not seen in
normal cornea. Immunostaining for GF and GFR in the normal cornea of VIP-/vs. WT mice were similar for both. However, at 1 day p.i., VIP-/- vs. WT mice had
more intense EGF and HGF, similar FGFR, and reduced FGF, EGFR, and HGFR
staining. VIP antagonist treatment decreased protein levels for GFR at 5 days p.i.
in both B6 and BALB/c mice, with no significant changes in normal cornea.
Conclusions: The data show that endogenous VIP is not requisite for GF or
GFR expression in the normal cornea, but after infection, its absence or
reduction is critical for their regulation.
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INTRODUCTION
Pseudomonas (P.) aeruginosa, an opportunistic, Gram-negative pathogen, is
one of the most virulent organisms associated with microbial keratitis and is often
associated with contact lens use (Wilhelmus, 1987). Infections progress rapidly
and lead to inflammatory epithelial edema, stromal infiltration, corneal ulceration,
and oftentimes vision loss (Hazlett et al., 2004). Experimental murine models of
the disease have been established: Th1 responder mouse strains (e.g., C57BL/6,
B6) are susceptible (cornea perforates), whereas Th2 responder strains (e.g.,
BALB/c) are resistant (cornea heals) (Hazlett et al., 2000).
In previous studies using these murine models, we provided evidence that an
anti-inflammatory neuropeptide, vasoactive intestinal peptide (VIP) promotes
resistance against P. aeruginosa corneal infection by regulation of cytokine
production and subsequent alteration of the host inflammatory cell response
(Szliter et al., 2007). In addition, recent studies from this laboratory have
provided mechanistic information that VIP treatment modulates keratitis through
regulation of growth factors, angiogenic molecules, beta defensins (Jiang et al.,
2011), and Toll-like receptors (TLR) (Jiang et al., 2012a) in the infected cornea,
contributing to healing. However, whether endogenous VIP is required for
production of growth factors (GF) or growth factor receptors (GFR) in the normal,
uninfected cornea and after infection remains untested. This is of importance to
determine, since it has been demonstrated in other experimental models
(Woodworth et al., 2005; Ware and Matthey, 2002) that one of the ways that
inflammation can be regulated is through growth factor binding to their receptors.
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Thus, the current study investigated the expression of growth factors and their
receptors in the normal and infected cornea of VIP knockout (VIP-/-) vs. wild-type
(WT) mice. Data from the studies provide evidence that the normal cornea of
both groups of mice is similar morphologically and have a similar pattern of GF
and GFR expression, suggesting that endogenous VIP is not requisite for their
expression. However, after infection, corneal perforation occurred more rapidly (2
days p.i.) in knockout vs. WT mice and real time RT-PCR and immunostaining
studies showed disparate expression of GF and their receptors in the two groups.
As the GFR appeared to be most consistently affected, B6 and BALB/c mice
were treated with a VIP antagonist, infected, and tested for GFR expression. In
this experiment, GFR proteins were reduced for both murine strains, confirming
the trend in the knockout data. Overall, the current study provides evidence that
endogenous VIP is not required for normal corneal expression of GF or GFR.
However, if it is absent or reduced, GFs and their receptors are dysregulated and
the infected cornea perforates rapidly.
MATERIALS AND METHODS
Infection. Eight-week-old, female, C57BL/6 VIP-/- (B6.129S4-Viptm1Clw/J) and
BALB/c mice, purchased from The Jackson Laboratory (Bar Harbor, ME), were
anesthetized with ethyl ether and placed beneath a stereoscopic microscope at
40X magnification. The cornea of the left eye was wounded (Huang et al., 2006)
and a 5-µl aliquot containing 1.0 x 106 CFU/µL of P. aeruginosa (American Type
Culture Collection, strain 19660, Manassas, VA) delivered topically. Animals
were treated humanely and in compliance with the Association for Research in
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Vision and Ophthalmology Statement on the Use of Animals in Ophthalmic and
Vision Research.
Ocular response to bacterial infection. Corneal disease was graded (Hazlett
et al., 1987): 0 = clear or slight opacity, partially or fully covering the pupil; +1 =
slight opacity, fully covering the anterior segment; +2 = dense opacity, partially or
fully covering the pupil; +3 = dense opacity, covering the entire anterior segment;
and +4 = corneal perforation or phthisis. After infection, a clinical score was
recorded (days 1 and 2) for each group of mice (n=5/group/treatment).
VIP antagonist treatment. BALB/c and B6 mice (n=5/group/time/assay) were
injected intraperitoneally with 100 µL PBS containing 10 µg VIP antagonist
(McClellan et al., 2008) (Bachem, Torrence, CA) on days −1, 0 (day of infection),
and daily through 5 days p.i. Control mice were similarly injected with PBS.
Normal uninfected and infected corneas were collected at 5 days p.i. for real-time
RT-PCR mRNA detection and ELISA assay.
Real-time RT-PCR. Total RNA was isolated from an individual cornea using
RNA

STAT-60™

(Tel-Test,

Friendswood,

TX),

per

the

manufacturer’s

recommendations, and quantitated spectrophotometrically (260 nm). One
microgram of total RNA was reverse transcribed using Moloney murine leukemia
virus (M-MLV) reverse transcriptase. The 20 µl reaction mixture containing 200 U
of M-MLV-reverse transcriptase, 10 U of RNase Inhibitor, 500 ng of oligo (dT)
primers, 10 mM deoxyribonucleotide triphosphate (dNTP), 100 mM dityhiothreitol
(DTT), and M-MLV reaction buffer (Invitrogen, Carlsbad, CA). After, cDNA was
amplified using SYBR Green Master Mix (Bio-Rad, Hercules, CA), per the

81
manufacture’s recommendation. Briefly, the 20 µL reaction system contained: 10
µL of SYBR Green PCR Master Mix, 0.5 µM primers, 2 µL of cDNA (diluted
1/25), and diethylpyrocarbonate water. All primer sets for the PCR array were
purchased as a 96-well plate (RT2 Profiler Mouse Wound Healing PCR Array;
SABiosciences Corporation, Frederick, MD). The individual primer sets were
designed using PrimerQuest (Integrated DNA Technologies, Coralville, Iowa).
Sequences of primers for β-actin, EGF, EGFR, FGF, FGFR, HGF, and HGFR are
shown (Table 3).
Gene

GenBank No.

β-Actin

NM_007393.3

EGF

NM_010113.3

EGFR

NM_007912.4

FGF-7

NM_008008.4

FGFR2

NM_010207.2

HGF

NM_010427.4

HGFR
(c-met)

NM_010427.4

Primer Sequence (5’ - 3’)
F - GAT TAC TGC TCT GGC TCC TAG C
R - GAC TCA TCG TAC TCC TGC TTG C
F - ACG GTT TGC CTC TTT TCC TT
R - GTT CCA AGC GTT CCT GAG AG
F - GTG GAG GGA CAT CGT CCA AA
R - ATT GGG ACA GCT TGG ATC ACA T
F - AAC AGC TAC AAC ATC ATG GAA ATC AG
R - AAT CAG TTC TTT GAA GTT GCA ATC CT
F - GTG CTT ATT GGG GAG TAT CTC CA
R - GAT CCA AGT TTC ACT GTC TAC CG
F - ACT TCT GCC GGT CCT GTT G
R - GGG ATG GCG ACA TGA AGC A
F - GTG AAC ATG AAG TAT CAG CTC CC
R - TGT AGT TTG TGG CTC CGA GAT

Size
(bp)
147
130
100
153
102
66
100

Table 3. Nucleotide sequence of the primers used in PCR amplification.

Quantitative real-time RT-PCR was performed using the MyiQ single color
real-time RT-PCR detection system (Bio-Rad). Optimal conditions for PCR
amplification of cDNA were established using routine methods (Heid et al., 1996).
Relative mRNA levels were calculated after normalization to β-actin.
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Immunofluorescent staining. Normal uninfected and infected eyes were
enucleated (n=3/group/time) at 1 day p.i. from WT and VIP-/- mice, immersed in
1X Dulbecco’s PBS (Mediatech, Inc., Manassas, VA), embedded in Tissue-Tek
OCT compound (Sakura Finetek USA, Torrance, CA) and frozen in liquid
nitrogen. Ten-micrometer sections were cut, mounted to poly-L-lysine-coated
glass slides, and stored at 37°C overnight. After a 2 min fixation in acetone,
slides were blocked with 10 mM sodium phosphate buffer containing 2.5% BSA
and donkey IgG (1:100) for 30 min at room temperature. Then, sections were
incubated for 1 h with goat anti-mouse EGF (15 µg/mL; R&D Systems,
Minneapolis, MN) or goat anti-mouse HGF (15 µg/mL; R&D Systems) antibody.
Antibodies for EGF and HGF were incubated simultaneously with antibodies for
their receptors, goat anti-mouse EGFR (15 µg/mL; R&D Systems) or goat antimouse HGFR (15 µg/mL; R&D Systems). This was followed by secondary
antibodies, Alexa Fluor 594-conjugated donkey anti-goat antibody (for EGF and
HGF, respectively, 1:1500; Invitrogen), and Alexa Fluor 633-conjugated donkey
anti-goat antibody (for EGFR and HGFR, respectively, 1:1500; Invitrogen) for
another hour.
Staining for FGF and its receptor, FGFR was done sequentially. After
incubating the sections with goat anti-mouse FGF antibody (1:100, Santa Cruz
Biotechnology, Santa Cruz, CA) for 1 h followed by the secondary Alexa Fluor
633-conjugated donkey anti-goat (1:2000; Invitrogen) for another hour, sections
were incubated with rabbit anti-mouse FGFR antibody (1:100, Santa Cruz), 1 h,
and Alexa Fluor 546-conjugated donkey anti-rabbit secondary (1:1500;
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Invitrogen) for another hour. Controls were similarly treated, but the primary
antibodies were replaced with the same host IgG (1:1000), ChromPure goat or
rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA). Finally,
sections were visualized and digital images captured with a Leica TCS SP2
confocal laser-scanning microscope (Leica Microsystems, Buffalo Grove, IL).
Bacterial plate counts. Corneas from PBS- or VIP antagonist-treated B6 mice
were collected (n = 5/group/time) at 1 and 5 days p.i. and the number of viable
bacteria were quantitated. Individual corneas were homogenized in sterile water
containing 0.85% (wt/vol) NaCl containing 0.25% BSA. Serial 10-fold dilutions of
the samples were plated on pseudomonas isolation agar (Becton Dickinson
Company, Sparks, MD) in triplicate and plates were incubated overnight at 37°C
and bacteria counted. Results are reported as log10 number of CFU per cornea ±
SEM.
Histopathology. For histopathology, whole infected eyes (n=3/group) were
enucleated from PBS- and VIP antagonist-treated B6 mice at 5 days p.i.,
immersed in PBS, rinsed, and fixed in 1% osmium tetroxide, 2.5%
glutaraldehyde, and 0.2 M Sorenson’s phosphate buffer (pH 7.4) (1:1:1) at 4°C
for 3 hours. Eyes were rinsed with 0.1 M phosphate buffer, dehydrated in graded
ethanols and propylene oxide, and then infiltrated and embedded in Eponaraldite. Thick sections (1.5 µm) were cut, stained, observed, and photographed
as described before (Huang et al., 2006) with a photomicroscope (Leica
DM4000B, Leica Microsystems Inc., Buffalo Grove, IL).
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ELISA. Protein levels for GFR were tested using ELISA kits. Corneas from PBSand VIP antagonist-treated mice were individually collected (n=5/group/time)
from normal uninfected and infected corneas at 5 days p.i. For EGFR (EIAab
Science Co. Ltd, Wuhan, China), for HGFR (R&D Systems) and for FGFR
(MyBioSource, San Diego, CA), corneas were homogenized in 0.5 mL of PBS
with 0.1% Tween 20 and protease inhibitor (1 tablet/10 mL, Roche Diagnostics,
Indianapolis, IN). All samples were centrifuged at 13,000 rpm for 5 min and an
aliquot of each supernatant was assayed in duplicate per the manufacturer’s
instructions. Sensitivities of the ELISA assays were <0.08 ng/mL for EGFR,
<10.0 µg/mL for HGFR, and <0.1 ng/mL for FGFR.
Statistics. The difference in clinical score between two groups was tested by the
Mann-Whitney U test. For all other experiments, an unpaired, two-tailed
Student’s t test (for comparisons between two groups) was used. p<0.05 was
considered to be statistically significant.
RESULTS
Ocular response in VIP-/- mice. VIP-/- vs. WT mice showed similar disease
scores at 1 day after infection. At 2 days p.i., a significantly higher mean clinical
score (Fig. 23A; p<0.05), indicative of worsened disease and/or perforation was
recorded for the knockout mice. Typical responses for each of the two groups
was documented by photography using a slit lamp and showed that WT (B) mice
had opacity over the anterior segment, while VIP-/- (C) mice exhibited corneal
perforation, with the remainder of the eye heavily opaque due to the presence of
an inflammatory infiltrate.
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-/-

Figure 23. VIP and WT B6 mice. Clinical scores (A) indicated statistically significant differences
at 2 days p.i. between groups. Photographs taken with a slit lamp at 2 days p.i. showed early
-/perforation in VIP (C) vs. WT (B) mice. Magnification=7X.

PCR array and real-time RT-PCR. To determine whether endogenous VIP is
required for GF production, mRNA levels of 84 wound healing-related genes
were profiled by PCR array at 2 days p.i. (Table 4). Eighteen of these GF and
GENE

FOLD UP- OR DOWNREGULATION

Angpt
Csf2
Csf3
Ctgf
Egf
Egfr
Fgf10
Fgf2
Fgf7
Hbegf
Hgf
Igf1
Mif
Pdgfa
Tgfa
Tgfb1
Tnf
Vegfa

-6.45
-1.79
1.03
-2.06
1.47
-1.83
4.69
-1.41
-5.03
-2.11
1.25
-3.63
1.21
1.16
-2.03
1.45
1.92
1.27
2

Table 4. Selected GFs from The Mouse Wound Healing RT Profiler
-/VIP with WT mice.

TM

PCR array comparing
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GF-related molecules (e.g., EGF, EGFR, FGF, and HGF) were disparately
changed in VIP-/- compared with WT B6 mice and are listed in Table 4. RT-PCR
was used to selectively confirm the array data and to test for FGFR and HGFR
that are receptors for FGF and HGF, but not included on the array. In the normal
uninfected cornea, we found no significant difference at the mRNA level between

Figure 24. GF and GFR mRNA expression. At 2 days p.i., EGF (A) and HGF (E) were
-/significantly increased, while FGF (C) mRNA levels were significantly decreased in VIP vs. WT
mice. EGFR (B) and HGFR (F) were decreased significantly, while FGFR (D) mRNA was similar
in the two groups. No significant changes between the two groups were seen in normal cornea.

the two mouse groups for GF or GFR expression (Fig. 24 A-F). However, at 2
days p.i., VIP-/- vs. WT mice showed significantly increased mRNA levels for EGF
(Fig. 24A, p<0.01) and HGF (Fig. 24E, p=0.01), but lower levels of FGF (Fig.
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24C, p<0.01). Growth factor receptors, EGFR (Fig. 24B, p<0.01) and HGFR (Fig.
24F, p<0.01) were significantly decreased in VIP-/- vs. WT mice, with no
significant changes to FGFR (Fig. 24D).

Figure 25. GF immunostaining (red) at 1 day p.i. Greater staining intensity for EGF and HGF,
-/with reduced intensity for FGF was seen in VIP compared to WT B6 mice. Negative controls, in
which the primary antibody was replaced with a species-specific IgG, showed no positive
staining. Magnification=170X.

Immunostaining. Immunostaining confirmed the mRNA data above and showed
no differences between the two groups of mice in the normal cornea for either the
GFs (red; Appendix A, Supplementary Fig. S1) or for the GFRs (blue, Appendix
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A, Supplementary Fig. S2). When comparing the two groups at 1 day p.i. (red,
Fig. 25), immunostaining of the cornea of VIP-/- vs. WT mice revealed increased
EGF and HGF, while FGF staining was decreased. For the GFRs, comparison in
immunostaining between the two groups at 1 day p.i. (blue, Fig. 26) revealed that

Figure 26. GFR immunostaining (blue) at 1 day p.i. Staining for GFRs was less intense for EGFR
-/and HGFR in VIP compared to WT B6 mice. No difference for FGFR was noted between
groups. Negative controls, in which the primary antibody was replaced with a species-specific
IgG, showed no positive staining. Magnification=170X.
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VIP-/- mice had decreased EGFR and HGFR staining, while staining for FGFR
was similar. All controls (Appendix A, Supplementary Figs. S1, S2; and Figs. 25
and 26), in which the primary antibody was replaced with same species IgG,
were negative for immunostaining.
Bacterial counts. To determine whether VIP antagonist treatment correlated
with increased bacterial number in the cornea, bacterial plate counts (Fig. 27A)
were used to detect viable bacteria in the infected cornea of mice treated with
VIP antagonist vs. PBS at 1 and 5 days p.i. When compared with controls, VIP
antagonist treatment led to increased bacterial plate counts at 1 (p<0.05) and 5
days p.i. (p<0.001).

Figure 27. VIP antagonist vs. PBS treatment significantly increased bacterial plate counts at 1
and 5 days p.i. (A). Histopathology at 5 days p.i. shows that the cornea of VIP antagonist-treated
B6 mice (C) was perforated, whereas the cornea of PBS-treated B6 mice (B) had more intact
stromal cytoarchitecture and was not perforated. Magnification=9.5X.

Histopathology. VIP antagonist-treated B6 mice (Fig. 27C) exhibited denudation
of the corneal epithelium, stromal degradation, severe edema, anterior chamber
inflammation, and perforation. In contrast, the cornea of PBS-treated mice (Fig.
5B) was thinned, but not perforated.
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Real-time RT-PCR. Next, to further test the effects of VIP on GF and GFR
expression, real-time RT-PCR was done using B6 mice treated with a VIP
antagonist vs. PBS. Similar to the VIP-/- experiments, there was no significant

Figure 28. GF and GFR mRNA expression. EGF (A) and HGF (E) were significantly increased,
while FGF (C) was decreased in VIP antagonist-treated B6 mice at 5 days p.i. EGFR (B) and
HGFR (F) were significantly decreased with no difference in FGFR (D) after VIP antagonist
treatment. No difference was detected between groups in normal uninfected cornea.

difference between the two groups of mice at the mRNA level in either GFs or
GFRs in the normal uninfected cornea (Fig. 28A-F). However, at 5 days p.i., VIP
antagonist- vs. PBS-treated mice showed significantly increased mRNA levels for
EGF (Fig. 28A, p=0.01) and HGF (Fig. 28E, p<0.01), with decreased levels for
FGF (Fig. 28C, p=0.05). Growth factor receptors, EGFR (Fig. 28B, p=0.01) and

91
HGFR (Fig. 28F, p=0.05), were significantly decreased in VIP antagonist- vs.
PBS-treated mice, while there was no significant change for FGFR (Fig. 28D).
ELISA. GFRs were tested at 5 days p.i. in B6 (Fig. 29 A, C, E) and BALB/c (Fig.
29 B, D, F) mice after treatment with VIP antagonist. For B6 mice, treatment with
the VIP antagonist resulted in reduced levels of EGFR (A), although not
significant, while reduction in both FGFR (C, p=0.05) and HGFR (E, p<0.01)
were significant. For BALB/c mice, VIP antagonist treatment significantly reduced
all three GFR, EGFR (B, p<0.001), FGFR (D, p<0.01) and HGFR (F, p<0.01). No
difference in GFRs between groups was detected in normal cornea.

Figure 29. GFR ELISA analysis. VIP antagonist vs. PBS treatment decreased GFR (A-F) in both
B6 and BALB/c mice at 5 days p.i. All were significant except for EGFR (A). No significant
changes were seen in the normal cornea between the two groups.
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DISCUSSION
The neuropeptide VIP is a multifunctional molecule that regulates immune
reactions and also participates in the maintenance and restoration of immune
homeostasis (Souza-Moreira et al., 2011). In addition, it has been considered in
itself to be a growth factor (Gressens et al., 1997) as well as a type 2 cytokine
(Pozo and Delgado, 2004).
In prior work, this laboratory has provided evidence that treatment with
synthetic VIP regulates expression of pro- and anti-inflammatory cytokines
(Szliter et al., 2007), growth factors (Jiang et al., 2011), and TLR (Jiang et al.,
2012a) in P. aeruginosa-induced keratitis. This leads to decreased stromal
destruction in a B6 mouse model in which the untreated, infected cornea
perforates within about 1 week after experimental infection (Szliter et al., 2007).
The present study, using VIP-/- mice, tested whether endogenous absence of
VIP, or its reduction using an antagonist, contributed to modulation of growth
factors and their receptors. No differences in either GFs or GFRs were detected
in the normal cornea by either RT-PCR or by immunostaining. Neither were there
detectable differences in corneal morphology between the two groups. In
contrast, in other models, the absence of VIP has been shown to lead to overall
altered intestinal morphology, as well as thickening of smooth muscle and
increased villi length in the bowel (Lelievre et al., 2007). In whole, cultured (day
9.5) mouse embryos, VIP regulated insulin growth factor-I and embryonic
development and when pregnant mice were treated with a VIP antagonist,
inhibition of embryonic growth occurred (Servoss et al., 2001).
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After infection, in the absence of the neuropeptide, GFs and GFRs were
dysregulated when tested by PCR array, RT-PCR, and immunostaining and the
cornea perforated more rapidly (within 2 days after infection) for the majority of
the knockout vs. WT mice. Furthermore, either the endogenous absence of VIP
or antagonist treatment of B6 mice led to this dysregulation. Specifically, VIP
antagonist treatment of B6 mice reduced all three GFRs at the mRNA level (all
significantly except for FGFR). And when either B6 or BALB/c mice were treated
with a VIP antagonist, GFR protein levels were decreased in both strains of mice
when compared with controls.
In this regard, others previously have shown interaction of VIP with the
EGFR. In this regard, in vitro studies have shown that Gq protein-coupled
receptor agonists such as VIP can directly activate (phosphorylate) the EGFR in
T84 colonic epithelial cells by signaling pathways involving cAMP and protein
kinase A and thereby regulate Cl- secretion (Bertelsen et al., 2004). Previous
studies have also shown that VIP receptors are Gs- (VPAC1/2) (Couvineau and
Laburthe, 2012) and Gq-coupled [VPAC2 (MacKenzie et al., 2001) and PAC1
(Nishimoto et al., 2007)]. cAMP, the downstream molecule of Gs-coupled
signaling, has been shown to increase nerve growth factor (NGF)-triggered
signaling and differentiation in rat adrenal pheochromocytoma PC12 cells (Chen
et al., 2010). On the other hand, phospholipase C-ε, the downstream molecule of
Gq signaling, augments EGF-dependent COS-7 cell growth by inhibiting EGFR
downregulation (Yun et al., 2008). Therefore, in the study reported herein, we
cannot exclude the possibility that VIP binds to VPAC1/2 (Gs-coupled) to activate
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cAMP, and/or binds PAC1 and VPAC2 (Gq-coupled) to activate phospholipase
C. The activated cAMP and/or phospholipase C, consequently, could regulate
EGF and EGFR expression. In another study, it was reported that during
infection of human alveolar epithelial cells with Pseudomonas fluorescens, a
Gram-negative rod, blocking EGFR increased epithelial susceptibility to
pathogen-induced epithelial cell death (Choi et al., 2011), consistent with,
although not tested, in our keratitis model.
Another growth factor, FGF-7/KGF (FGF) and its receptor (FGFR), were both
found to reduce Pseudomonas infection in a lung model, through reducing
bacterial load, since intratracheal FGF was found to increase clearance of P.
aeruginosa (Viget et al., 2000). Another study using an experimental burn model
in human keratinocytes, also found that when FGF was added to P. aeruginosa
in the presence of keratinocytes, bacterial growth was inhibited and the same
was observed when genetically modified keratinocytes were used (Sobral et al.,
2007). In addition, P. aeruginosa infection in a bioengineered skin model, in
which FGF was expressed in diploid human keratinocytes, led to increased levels
of antimicrobials β-defensin-2 and cathelicidin (LL-37) production and reduced
bacterial load when compared with controls (Erdag et al., 2004).
The current study essentially agrees with these past studies, in that absence
of VIP or treatment with a VIP antagonist that dysregulates GF and GFR,
contributed to earlier corneal perforation and/or increased bacterial load (tested
only in antagonist treated mice). Previous studies from this laboratory also found
that treatment using a GF mixture, composed of EGF, FGF, and HGF, increased
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antimicrobial peptides including murine β-defensin-2 (mBD-2) and mBD-3
expression, as well as decreasing bacterial plate counts, resulting in less disease
severity in the infected cornea (Jiang et al., 2011). FGF also has been shown to
promote wound healing in skin epithelium (Marchese et al., 1995) and
participates in lung epithelial repair as well (Ware and Matthay, 2002). Since
many cases of bacterial keratitis result either directly or indirectly from disruption
of the corneal epithelium (O’Brien, 2003), it also is possible that earlier
perforation observed in VIP-/- mice may be due to reduced FGF levels with
subsequent epithelial defect. HGFR mRNA and protein (immunostaining) are
also decreased in the VIP-/- mice. HGFR recognizes HGF (that has antiinflammatory properties) in that it can target vascular endothelial cells and disrupt
nuclear factor-kappa B (NFκB) signaling in these cells (Gong et al., 2006), critical
to regulating inflammatory cytokines.
Overall, this study provides evidence that VIP is not required for GF or GFR
expression in the normal cornea. However, if the neuropeptide is endogenously
absent or reduced through treatment, GF and GFR are dysregulated, bacterial
load is increased, and disease progression is enhanced.
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APPENDIX

Supplementary Figure S1. GF immunostaining in normal cornea. GF staining (red) was similar
-/in VIP and WT B6 mice. Negative controls, in which the primary antibody was replaced with a
species-specific IgG, showed no positive staining. Magnification=170X.

97

Supplementary Figure S2. GFR immunostaining in normal cornea. GFR staining (blue) did not
-/differ between VIP and WT B6 mice. Negative controls, in which the primary antibody was
replaced with a species-specific IgG, showed no positive staining. Magnification=170X.
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This body of work examined the mechanism by which SP regulates host
immunity, specifically, its control of growth factors and TLR expression in the P.
aeruginosa-infected cornea. The role of mTOR and VIP in corneal infection and
inflammation also was tested.
SP has a dual role in bacterial infection, unexpectedly upregulating growth
factor production. This was accompanied by macrophage-specific upregulation of
pro-inflammatory cytokines, downregulation of anti-inflammatory cytokines, and
upregulation of anti-apoptotic genes, as well as a decrease in arginase-producing
macrophages (M2 cells), important in stromal healing in these mice. All of these
lead to worsened disease, despite the stimulatory effects on growth factor
production and contraindicate clinical use of SP in cornea to promote wound
healing, if an infection is present or suspected.
Next, we provided evidence that IL-10 is regulated in the infected cornea via
the mTOR pathway. This conclusion is based upon data showing that inhibition
of mTOR by rapamycin decreased anti-inflammatory cytokines, particularly IL-10,
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and upregulated several pro-inflammatory cytokines (IL-12p40, IFN-γ) and their
regulators/effectors. Furthermore, rapamycin downregulated caspase-3 and
upregulated Bcl-2, the latter prolonging inflammatory cell viability, possibly further
contributing to stromal destruction and unresolved disease.
Finally, we demonstrated that endogenous VIP is not required for normal
corneal expression of GF or their receptors. However, if VIP is absent or
reduced, GFs and their receptors are dysregulated and the infected cornea
perforates rapidly.
In summary, the impact of the neuropeptides SP and VIP on growth factors
and Toll-like receptors in the cornea provides insight and direction in the
development of better therapeutics to regulate corneal infection and other
inflammatory pathologies.
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